

PLOS ONE

Bioengineered phytomolecules-capped silver nanoparticles using *Carissa carandas* leaf extract to embed on to urinary catheter to combat UTI pathogens

--Manuscript Draft--

Manuscript Number:	PONE-D-21-17789R1
Article Type:	Research Article
Full Title:	Bioengineered phytomolecules-capped silver nanoparticles using <i>Carissa carandas</i> leaf extract to embed on to urinary catheter to combat UTI pathogens
Short Title:	Bioengineered phytomolecules-capped silver nanoparticles using <i>Carissa carandas</i> leaf extract
Corresponding Author:	Muthupandian Saravanan, Ph.D., Mekelle University College of Health Sciences Mekelle, Ethiopia ETHIOPIA
Keywords:	AgNPs; uropathogens; Urethral catheter; Surface modification; biocompatibility; Synergistic effect
Abstract:	<p>Rising incidents of urinary tract infections (UTIs) among catheterized patients is a noteworthy problem in clinic due to their colonization of uropathogens on abiotic surfaces. Herein, we have examined the surface modification of urinary catheter by embedding with eco-friendly synthesized phytomolecules-capped silver nanoparticles (AgNPs) to prevent the invasion and colonization of uropathogens. The preliminary confirmation of AgNPs production in the reaction mixture was witnessed by the colour change and surface resonance plasmon (SRP) band at 410nm by UV-visible spectroscopy. The morphology, size, crystalline nature, and elemental composition of attained AgNPs were further confirmed by the transmission electron microscopy (TEM), selected area electron diffraction (SAED), X-ray diffraction (XRD) technique, Scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS). The functional groups of AgNPs with stabilization/capped phytochemicals were detected by Fourier-transform infrared spectroscopy (FTIR). Further, antibiofilm activity of synthesized AgNPs against biofilm producers such as <i>Staphylococcus aureus</i>, <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> were determined by viability assays and micrographically. AgNPs coated and coating-free catheters performed to treat with bacterial pathogen to analyze the mat formation and disruption of biofilm formation. Synergistic effect of AgNPs with antibiotic reveals that it can enhance the activity of antibiotics, AgNPs coated catheter revealed that, it has potential antimicrobial activity and antibiofilm activity. In summary, <i>C. carandas</i> leaf extract mediated synthesized AgNPs will open a new avenue and a promising template to embed on urinary catheter to control clinical pathogens.</p>
Order of Authors:	<p>Haajira Beevi Habeeb Rahuman</p> <p>Ranjithkumar Dhandapani</p> <p>Thangavelu Sathiamoorthi</p> <p>Ragul Paramasivam</p> <p>Velmurugan Palanivel</p> <p>Muthupandian Saravanan, Ph.D.,</p>
Response to Reviewers:	<p>Plos One Journal Modifications</p> <ol style="list-style-type: none"> 1.Revised manuscript has been changed to the style requirements of PLOS ONE 2.Tables has been included in the revised manuscript and removed separate file 3.We didn't receive any funding for this work so please change it to "The authors received no specific funding for this work" 4.Minimal data set has been included as a supplementary file. 5.The figure 10,11 is similar but not identical to the original image and is therefore for illustrative purpose only and the figure 5 has been changed in the revised manuscript. <p>Response to reviewers comments</p> <p>We are thankful to the Reviewers 1,2, and 3 for their kind and constructive feedback.</p>

As suggested by the reviewers, we have changed/addressed the following comments and the same has been highlighted in the revised manuscript with the response to the reviewers' file.

NoPage/SectionComments by Reviewer #1Response by the authors

1IntroductionIn the introduction, authors should justify why they decided to use Ag NPs and leaves of *C. carandas*? Highlight their advantages, because we cannot simply use something because just it is available!We have improved the introduction part as per your suggestion. Reviewer can find the improved part at line 76-79 and line 86-94 in the revised manuscript.

2Line 60Line 60, "Leaves of *C. carandas* were used to yield Ag NPs", I think you need to rephrase this sentence, as leaf extract can only be used to stabilize formed Ag NPs and / or reduce the precursor solution of silver nitrate into Ag NPs.We have rephrased the sentence and can be found at line 95-97 of the revised manuscript.

3Line 93Line 93, wavelength of Cu-K α radiation is not correct, the correct value is 1.5406 ÅCorrect value can be found at line 141 in the revised manuscript

4Line 225-line 93In line 225, authors used Scherrer formula to determine crystalline size, and they mentioned non-correct wavelength in

Line 93, then accordingly, the calculated size will not be correct. Please check this size again.The wavelength has been corrected in line 141 of revised manuscript. Therefore, size mentioned in the line 313 of revised manuscript doesn't need any modification
5XRD pattern contains non-assigned peaks, please explain.Detailed description was made and can be found at line 316-320in the revised manuscript

6on FTIR spectra, it is better to highlight, peaks confirming the conjugation between Ag NPs and the extractHighlighted peaks confirm the capping can be found at Fig 4 D in the revised manuscript

7On SAED pattern, you should assign the crystalline planes and match them with those obtained by XRD.Fig 4 C of the revised manuscript shows the marked diffraction rings corresponds to the peaks obtained in XRD

8Fig.2Fig. 2 is not clear; it is better to draw the data using suitable softwareSuggested modifications were done in the revised manuscript and can be found as Fig 2 and Fig 3

9Fig. 3Fig. 3 it is hard to see the label, also indicate the ZOI on the figure for each tested sample.Suggested modification are done in the revised manuscript and can be found as Fig 4 and Fig 5

10Fig.4Fig.4, error bars should be addedSuggested modification are done in the revised manuscript and can be found as Fig 7

11Fig. 9On Fig. 9, assign Ag NPs.Suggested modifications are done in the revised manuscript and can be found as Fig 10

NoPage/SectionComments by Reviewer #2Response by the authors

1Fig 10The Fig 10 is inappropriate, require evidence-based pathwayThe actual mechanism was not found through our study but we are coming up with the mechanism already available in the literature and we have changed the text in figure instead of *Carisa carandas* AgNPs it is mentioned as plant AgNPs and also, we have widely discussed about the biofilm mechanism in the discussion part line 545-564

2Light Microscopy and Florescent Microscopy images shall be placed under suppl doct is placed under supplementary file as per your suggestion and can be found as Supplementary document in the revised manuscript

3Include CFLSM image for biofilm inhibitionAs stated in the financial disclosure this study does not have any funding it is very hard for us to afford this imaging as it is not available in our institutions. However, we will try to sort out this issue in the future studies.

4TEM is showing a cluster of AgNPs, required scale marked particlesSuggested modifications by the reviewer has been done and can be found at Fig 4 (A) in the revised manuscript

5Self-agglomeration of synthesized AgNPs on storage is requiredWe have found the AgNPs solution was stable for the period of two months under dark. Hence no agglomeration was taken place in the solution and then we lyophilized the AgNPs to obtain AgNPs powder for the purpose of application. Therefore, no chance of self-agglomeration takes place

6Language and presentation require editing e.g. In the Introduction *Pseudomonas* is written as *Pseudomon* asAll the necessary modifications were done in the revised manuscript

	<p>NoPage/SectionComments by Reviewer #3Response by the authors</p> <p>1All minor revisions are highlighted in manuscript file, these include suggestion for rewrite sentences, and simple changesAll the minor revisions were changed according to the suggestion of the reviewer in the revised manuscript</p> <p>2Abstract and introduction Grammar revision is suggested in some parts of these sections, in manuscript file are highlighted in yellow.The grammar revisions were changed according to the suggestion of the reviewer in the revised manuscript</p> <p>3Synthesis and optimization of AgNPs production Include units of Ag ion concentration, volume of leaf extract, etc.Suggested modifications by the reviewer has been done in the revised manuscript and can be found at line 122-134</p> <p>4Antibacterial activity I suggest modification of titles and subtitles order, and include some methodology description described in other method section. Include description about how the AgNPs concentration was calculated. Suggested modifications by the reviewer has been done and can be found at line 154-162 in the revised manuscript</p> <p>5Biofilm inhibition assay Indicate concentration of AgNPs in concentration units (i.e. mg/L) instead of volume units. If concentration and volume of AgNPs are equivalent please indicate and explainSuggested modifications by the reviewers has been done and can be found at line 224-226 and at line 237-250 in the revised manuscript</p> <p>6In Section 2.12 it is not clear the objective of this experiment, please justify.The experiment title has been changed and the objective has been well described at line 252-256 in the revised manuscript</p> <p>7Results I suggest to maintain the same subtitles used in methods section in order to establish an order and accordance between methods and resultsAs per the reviewer's suggestion, we have maintained the same subtitles in methods and results which can be found in the revised manuscript</p> <p>8I suggest include images of AgNPs suspensions obtained at different synthesis conditions (i.e. varying pH, leaf extract concentration, time reaction and Ag ions concentration)As per the reviewer suggestion the image for color of AgNPs synthesis has been added in Fig 1 and Fig 2 (A, B, C, D)</p>
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS ONE for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p>	<p>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>

Unfunded studies

Enter: *The author(s) received no specific funding for this work.*

Funded studies

Enter a statement with the following details:

- Initials of the authors who received each award
- Grant numbers awarded to each author
- The full name of each funder
- URL of each funder website
- Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript?
- **NO** - Include this sentence at the end of your statement: *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*
- **YES** - Specify the role(s) played.

* typeset

Competing Interests

Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any [competing interests](#) that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.

This statement is **required** for submission and **will appear in the published article** if the submission is accepted. Please make sure it is accurate and that any funding sources listed in your Funding Information later in the submission form are also declared in your Financial Disclosure statement.

View published research articles from [PLOS ONE](#) for specific examples.

The authors have declared that no competing interests exist.

NO authors have competing interests

Enter: *The authors have declared that no competing interests exist.*

Authors with competing interests

Enter competing interest details beginning with this statement:

I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]

* typeset

Ethics Statement

NA

Enter an ethics statement for this submission. This statement is required if the study involved:

- Human participants
- Human specimens or tissue
- Vertebrate animals or cephalopods
- Vertebrate embryos or tissues
- Field research

Write "N/A" if the submission does not require an ethics statement.

General guidance is provided below. Consult the [submission guidelines](#) for detailed instructions. **Make sure that all information entered here is included in the Methods section of the manuscript.**

Format for specific study types

Human Subject Research (involving human participants and/or tissue)

- Give the name of the institutional review board or ethics committee that approved the study
- Include the approval number and/or a statement indicating approval of this research
- Indicate the form of consent obtained (written/oral) or the reason that consent was not obtained (e.g. the data were analyzed anonymously)

Animal Research (involving vertebrate animals, embryos or tissues)

- Provide the name of the Institutional Animal Care and Use Committee (IACUC) or other relevant ethics board that reviewed the study protocol, and indicate whether they approved this research or granted a formal waiver of ethical approval
- Include an approval number if one was obtained
- If the study involved *non-human primates*, add *additional details* about animal welfare and steps taken to ameliorate suffering
- If anesthesia, euthanasia, or any kind of animal sacrifice is part of the study, include briefly which substances and/or methods were applied

Field Research

Include the following details if this study involves the collection of plant, animal, or other materials from a natural setting:

- Field permit number
- Name of the institution or relevant body that granted permission

Data Availability

Authors are required to make all data underlying the findings described fully available, without restriction, and from the time of publication. PLOS allows rare exceptions to address legal and ethical concerns. See the [PLOS Data Policy](#) and [FAQ](#) for detailed information.

Yes - all data are fully available without restriction

A Data Availability Statement describing where the data can be found is required at submission. Your answers to this question constitute the Data Availability Statement and **will be published in the article**, if accepted.

Important: Stating 'data available on request from the author' is not sufficient. If your data are only available upon request, select 'No' for the first question and explain your exceptional situation in the text box.

Do the authors confirm that all data underlying the findings described in their manuscript are fully available without restriction?

Describe where the data may be found in full sentences. If you are copying our sample text, replace any instances of XXX with the appropriate details.

- If the data are **held or will be held in a public repository**, include URLs, accession numbers or DOIs. If this information will only be available after acceptance, indicate this by ticking the box below. For example: *All XXX files are available from the XXX database (accession number(s) XXX, XXX).*
- If the data are all contained **within the manuscript and/or Supporting Information files**, enter the following:
All relevant data are within the manuscript and its Supporting Information files.
- If neither of these applies but you are able to provide **details of access elsewhere**, with or without limitations, please do so. For example:

Data cannot be shared publicly because of [XXX]. Data are available from the XXX Institutional Data Access / Ethics Committee (contact via XXX) for researchers who meet the criteria for access to confidential data.

The data underlying the results presented in the study are available from (include the name of the third party

All relevant data are within the manuscript and its Supporting Information files.

<p><i>and contact information or URL).</i></p> <ul style="list-style-type: none">• This text is appropriate if the data are owned by a third party and authors do not have permission to share the data. <p>* typeset</p>	
Additional data availability information:	Tick here if the URLs/accession numbers/DOIs will be available only after acceptance of the manuscript for publication so that we can ensure their inclusion before publication.

1 **Bioengineered phytomolecules-capped silver nanoparticles**
2 **using *Carissa carandas* leaf extract to embed on to urinary**
3 **catheter to combat UTI pathogens**

4 Haajira Beevi Habeeb Rahuman^{1¶}, Ranjithkumar Dhandapani^{1¶}, Velmurugan Palanivel^{2*},
5 Sathiamoorthi Thangavelu¹, Ragul Paramasivam³, Muthupandian Saravanan^{4,5*}

6

7 ¹ Department of Microbiology, Science Campus, Alagappa University, Karaikudi- 630 003,
8 Tamilnadu, India

9 ² Centre for for Material Engineering and Regenerative Medicine Bharath Institute of Higher
10 Education, Chennai, India.

11 ³ Chimertech Innovations LLP, Tamilnadu Veterinary and Animal Science University,
12 Chennai, India

13 ⁴ Division of Biomedical sciences, College of Health Sciences, School of Medicine, Mekelle,
14 Ethiopia.

15 ⁵ AMR and Nanomedicine Laboratory, Department of Pharmacology, Saveetha Dental
16 College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 600 077,
17 Chennai, India

18 ¶ These authors have contributed equally to this work

19

20 ***Corresponding authors:** Muthupandian Saravanan, Email: bioinfosaran@gmail.com,

21 Velmurugan Palanivel, Email: palanivelmurgan2008@gmail.com.

22

23

24 **Abstract**

25 Rising incidents of urinary tract infections (UTIs) among catheterized patients is a
26 noteworthy problem in clinic due to their colonization of uropathogens on abiotic surfaces.
27 Herein, we have examined the surface modification of urinary catheter by embedding with eco-
28 friendly synthesized phytomolecules-capped silver nanoparticles (AgNPs) to prevent the
29 invasion and colonization of uropathogens. The preliminary confirmation of AgNPs production
30 in the reaction mixture was witnessed by the colour change and surface resonance plasmon
31 (SRP) band at 410nm by UV–visible spectroscopy. The morphology, size, crystalline nature,
32 and elemental composition of attained AgNPs were further confirmed by the transmission
33 electron microscopy (TEM), selected area electron diffraction (SAED), X-ray diffraction
34 (XRD) technique, Scanning electron microscopy (SEM) and energy dispersive spectroscopy
35 (EDS). The functional groups of AgNPs with stabilization/capped phytochemicals were
36 detected by Fourier-transform infrared spectroscopy (FTIR). Further, antibiofilm activity of
37 synthesized AgNPs against biofilm producers such as *Staphylococcus aureus*, *Escherichia coli*
38 and *Pseudomonas aeruginosa* were determined by viability assays and micrographically.
39 AgNPs coated and coating-free catheters performed to treat with bacterial pathogen to analyze
40 the mat formation and disruption of biofilm formation. Synergistic effect of AgNPs with
41 antibiotic reveals that it can enhance the activity of antibiotics, AgNPs coated catheter revealed
42 that, it has potential antimicrobial activity and antibiofilm activity. In summary, *C. carandas*
43 leaf extract mediated synthesized AgNPs will open a new avenue and a promising template to
44 embed on urinary catheter to control clinical pathogens.

45 **Key words:** AgNPs, Uropathogens, Urethral catheter, Surface modification,
46 Biocompatibility, Synergistic effect.

47

48 **Introduction**

49 UTI is broadly defined as a symptomatic or asymptomatic infection in both upper and
50 lower urinary system which involves initial adhesion and colonization on the surface of the
51 medical devices (catheter). The bacteria implicated in UTIs are *Staphylococcus sp.*,
52 *Streptococcus sp.*, *Klebsiella sp.*, *Enterococcus sp.*, *Proteus sp.*, *Pseudomonas sp.*, and
53 *Escherichia coli* owing to its biofilm assembly capacity [1-3]. Among most of the UTI cases,
54 80% are allied with ingrained urinary catheters [4] and associated UTIs are foremost common
55 infection throughout the world [5]. The colonization of microbial community on medical
56 devices forms a polymicrobial aggregates called “biofilm”. Self-generated extracellular
57 polymeric matter adheres the surface of the hospital acquired devices give rise to implant
58 failure. It has been accounted that to control biofilm forming bacteria needs 1500 times higher
59 concentration of antibiotics when compared to planktonic bacteria [6]. The existence of urine
60 in urinary catheters makes an appropriate habitation for urease-positive microbes. The pH of
61 the urine increases due to the presence of ammonia which makes the deposition of calcium and
62 magnesium phosphate on catheter can ultimately leads to thorough constriction of the biofilm
63 on catheter over coating or crystalline biofilms [7]. The UTI bacteria cause serious concerns
64 due to spreading to kidney and cause acute or chronic pyelonephritis [8]. Increased antibiotic
65 resistance of biofilm was formed by extracellular polymeric substances (EPS) matrix, found in
66 the biofilm communities which makes the treatment ineffective [9]. A review by [8] Singha et
67 al., 2017 described the several attempts have been made to impregnating antimicrobial coating
68 on catheter with antibiotics, antimicrobial agents (both biocidal and antifouling), antimicrobial
69 peptides, bacteriophages, enzymes, nitric oxide, polyzwitterions, polymeric coating
70 modifications, liposomes. These coating have shown good antimicrobial activity *in vitro*,
71 however a few drawbacks are shortlisted including resistance development. Silver
72 nanoparticles produced from the phytochemicals of *C. carandas* leaf extract have been studied

73 as a major and promising antibacterial alternative and also inhibit the biofilm formation in UTI
74 pathogens. It was coated as an antimicrobial nanomaterial in the urinary catheter to prevent
75 catheter associated UTI infection.

76 Among the various inorganic metal nanoparticles, silver nanoparticles (AgNPs) have
77 gained its attention for various reasons such as low toxicity, environment friendly and also
78 known for its antibacterial activity against the bacteria exhibiting resistance to antibiotics [10].
79 Silver exhibits excellent antimicrobial activity and the production of nanomaterial through
80 physical and chemical approaches will have an adverse effect in environment due to the
81 adsorption of toxic substance as a reducing agent [11]. The system of phytochemical mediated
82 synthesis of nanomaterial is a promising eco-friendly, non-toxic, cheap substrate, easily
83 available, convenient and quickly processable to fabricate antimicrobial nanomaterial[11,12].
84 *C. carandas* belongs to the species of flowering shrub in dogbane family, Apocyanaceae.
85 *Carissa carandas* spread widely throughout the tropical and subtropical region of India. The
86 plant possessing phytochemical constituents has high medicinal values [13]. In traditional
87 medicine, *Carissa carandas* leaf, bark, fruit, root have been used to treat several human
88 ailments such as hepatomegaly, indigestion, amenorrhea, oedema, colic, piles, antipyretic,
89 fever, liver dysfunction, stomach pain, skin infections, intestinal worms, antimicrobial,
90 antifungal [14-16]. The leaf of *C. carandas* has anticancer, antimicrobial, antioxidant property
91 and non-mutagenic property [17]. The leaf decoction is used to treat against sporadic fever,
92 remedy for diarrhea, earache, syphilitic pain, oral inflammation and snake bite poisoning [18].
93 Since this plant has many medicinal values and very less literature availability for *C. carandas*
94 leaf extract.

95 In this research, the leaf extract of *C. carandas* was used to reduce the precursor
96 solution of silver nitrate to AgNPs and this production was optimized by modifying parameters
97 of synthesis such as pH, *C. carandas* leaf extract, metal ion concentration, and production time.

98 Characterization of synthesized AgNPs was done by UV Vis spectrophotometry, TEM, XRD,
99 EDS, FTIR and SAED pattern. The synthesized AgNPs was investigated for antimicrobial
100 activity and embedded on catheter to investigate the property as antimicrobial nanomaterial to
101 inhibit catheter associate UTI infection.

102 **Materials and Method**

103 **Chemicals and biological materials**

104 Fresh leaves of *C. carandas* were collected from Periyakulam, Theni District,
105 Tamilnadu, India (10.1239° N, 77.5475° E) and washed thoroughly to remove the dust. Silver
106 nitrate (AgNO₃), Muller Hinton Agar (MHA), Lysogenic broth (LB), trypticase soya broth
107 (TS) was acquired from Hi-media and used to assess antibacterial, antibiofilm assays. Bacterial
108 pathogens such as *Escherichia coli* AMB4 (MK788230), *Pseudomonas aeruginosa* AMB5
109 (clinical sample), *Staphylococcus aureus* AMB6 (Clinical sample) was maintained by
110 Department of Microbiology, Alagappa University, Science campus, Karaikudi, India.

111 **Extract preparation**

112 Cleaned *C. carandas* leaves were subjected to air dry and quantified the weight of 100
113 grams. Dried leaves were soaked in 300 mL of Millipore water and allowed to boil for 1 h at
114 80°C to avail decoction of leaf extract which was percolated through Whatmann no.1 filter
115 paper and stored at 4 °C for future use.

116 **Synthesis and optimization of AgNPs production**

117 The AgNPs synthesis was carried out by adding 1mL of filtered *C. carandas* leaf extracts
118 and 9mL of 1.25mM aqueous silver nitrate solution (AgNO₃) in the ratio of 1:9 was incubated at
119 ambient temperature under dark condition. Initial AgNPs production was confirmed by visual color
120 change from light yellow to dark brown color and scanning the absorbance along the UV-Vis range
121 (200-600 nm) of the electromagnetic spectra using an UV-Visible Spectrophotometer (Shimadzu

122 UV 1800, Japan). To achieve large scale production of AgNPs, optimization procedure was
123 followed by modifying the parameters like pH, substrate (extract), metal ion concentration and
124 production time. Briefly, pH of the solution was optimized by modifying the solution to various
125 pH 2, 3, 4, 5, 6, 7, 8, 9, 10 with 1mL substrate (extract) concentration and 0.1mM metal ion
126 concentration, left overnight under dark condition. Substrate concentration was optimized by
127 modifying the solution to various concentration like 0.1, 0.5, 0.75, 1, 1.25, 1.5, 1.75 mL with the
128 optimized pH as a standard and 0.1mM metal ion concentration, left overnight under dark
129 condition. Ag⁺ ion concentration was optimized by modifying the solution to various metal ion
130 concentration such as 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5mM with the optimized pH and
131 optimized substrate concentration, left overnight under dark condition. Then finally production
132 time was optimized by measuring the absorbance at various time intervals such as 0, 5, 10, 15, 20,
133 25, 30 mins with the optimized pH, substrate and metal ion concentration using UV-Visible
134 Spectrophotometer. With the optimized parameters the optimum production was set for the large-
135 scale production. The heterogeneous mixture was centrifuged at 12000 rpm for 20 min followed
136 by collection of pellets; washed with methanol: water ratio at 6:4 and lyophilized to obtain
137 nanoparticles powder.

138 **Characterization of nanoparticles**

139 XRD (X-ray diffraction) analysis of silver nanoparticles was recorded by P analytical
140 X' Pert PRO powder which was operated at a voltage of 40kV with the current of 30 mA using
141 Cu-K α radiation of wavelength 1.5406 Å in the 2 θ range of 20° - 80° to obtain the crystalline
142 structure of the AgNPs. Involvement of functional group in synthesis of nanoparticles and
143 capping material was monitored by FTIR (Fourier Transform Infrared spectrophotometer) and
144 performed to analyze the presence of functional groups of AgNPs and capping phytochemicals
145 using attenuated total reflectance (ATR) mode (Nicolet iS5, Thermo Fisher Scientific Inc.,
146 Marietta, GA, USA). EDX (Energy dispersive X-ray) analysis was performed to determinate

147 the elemental composition (Tescan VEGA 3SBH with Brukar easy). HR-TEM (High resolution
148 Transmission Electron microscope) (JEOL-2100+, Japan) and SAED (selected area Electron
149 Diffraction) pattern were analyzed to examine the size, crystalline structure and surface
150 morphology of AgNPs.

151 **Antibacterial activity**

152 Each test bacterial strain of 0.5 McFarland standards [19] was swabbed on MHA plates
153 using a sterile swab and a well of 8mm width was formed using a sterile well borer under
154 aseptic condition. Different concentrations of AgNPs 25, 50, 75, 100, 125 μ g/mL (1mg/mL
155 stock solution was prepared for synthesized AgNPs, from the stock solution 25 μ l was
156 dissolved in 975 μ l of DMSO to make 25 μ g/mL concentration and further concentrations were
157 prepared accordingly) were loaded in the MHA plates along with the DMSO as solvent control
158 and incubated at 37°C for 24 h. After incubation, zone of inhibition (ZoI) was measured to the
159 nearest millimeter from end of the well to end of the zone.

160 Comparison was made with AgNPs (125 μ g / mL), crude leaf extract (50 μ g/mL),
161 1.25mM AgNO₃ solution, 99.8% of DMSO as a solvent negative control and ciprofloxacin
162 (50 μ g/ml) as positive control for assessment were loaded consequently in the agar wells made
163 in MHA plate and incubated at 37°C for 24 h. After incubation, zone of inhibition (ZoI) was
164 measured to the nearest millimeter from end of the well to end of the zone.

165 **Minimum Inhibitory (MIC) and Minimum Bactericidal**

166 **Concentration (MBC)**

167 The MIC and MBC was performed to evaluate the efficiency of obtained AgNPs
168 to inhibit bacterial pathogens and protocol was followed according to the guidance of CLSI.
169 MIC was performed by 96 microtiter well plate by broth micro dilution method. 10⁶CFU/mL
170 concentration of bacterial inoculum (10 μ l) was inoculated with different concentrations of

171 AgNPs (20, 40, 60, 80, 100, 120, 140, and 160µg/ml) and incubated at 37 °C for 24 h. After
172 incubation well plates were recorded by ELISA reader at 590nm to assess its optical density
173 value. MIC was analyzed to determine the efficacy of appropriate concentration of AgNPs
174 required inhibiting the bacterial growth. The inhibition rate can be estimated as follows

$$175 \quad \% \text{ Inhibition rate} = 100 \times \frac{(OD_{\text{untreated}} - OD_{\text{well}})}{(OD_{\text{untreated}} - OD_{\text{blank}})} \quad (1)$$

176 Where $OD_{\text{untreated}}$ = optical density of bacterial cell without AgNPs, OD_{well} = optical density of
177 bacterial cell with AgNPs, OD_{blank} = sterile culture medium.

178 The MIC endpoint is the lowest concentration of silver nanoparticles where no visible growth
179 is seen in the well. The visual turbidity was noted, both before and after incubation of well
180 plate to confirm MIC value [20].

181 After incubation the titer plates were agitated gently for 10 min and the broth in the
182 well were plated on MHA plate and incubated during 24h, the CFU was counted and bacterial
183 viability was calculated in order to calculate the MBC. MBC cutoff occurs when 99.9% of the
184 microbial population is destroyed at the lowest concentration of AgNPs [20].

185 **Synergistic effect of silver nanoparticles with commercial** 186 **antibiotics**

187 Synergistic effect of silver nanoparticles with commercial antibiotics for uropathogens
188 was done by disk diffusion method. Commercial antibiotic discs were impregnated with
189 synthesized AgNPs (Ciprofloxacin -50mcg, Trimethoprim – 30 mcg, Gentamycin – 30 mcg)
190 in the concentration of 20µg/mL and allowed to air dry. Then MHA plates were prepared and
191 inoculated with overnight bacterial culture in the turbidity of 0.5% of McFarland standard.
192 Commercial antibiotic disc impregnated with AgNPs was placed on the MHA plates and
193 control plates were swabbed with test culture and placed with commercial discs aseptically.
194 These plates were incubated at 37 °C for 24 h and the zone of inhibition was measured[21].

195 **Qualitative assay for biofilm formation**

196 Qualitative assessment of the pathogen's biofilm potential was performed by test tube
197 method according to [7] Doll et al., 2016. Briefly, trypticase soy broth was inoculated with
198 loop full of mid-log phase pathogen and incubated at 37 °C for 24 h. Uninoculated broth was
199 considered as a control. The broth was removed 24 hours of incubation and tubes were cleaned
200 with sterile Phosphate buffered saline PBS with the pH of 7.4. The tubes were dried and stained
201 for 10 minutes with 0.1 percent crystal violet. Extra dye was removed with sterile distilled
202 water and stained film formed at the tube's base, indicating the development of biofilm [22].

203 **Quantitative assay for biofilm formation**

204 Development of static biofilm formation was confirmed by quantitative assay by
205 microtiter plate method. Mid-log phase culture was diluted ten times using a sterile media. The
206 culture was transferred to microtiter plate. The plates were incubated at 37 °C for 16h. After
207 incubation, planktonic cells were removed using PBS (pH 7.2) and dried, subsequently the
208 plates were stained with 125µL of 0.1 % CV solution. Dye in the well surface was solubilized
209 using 200µL of 30% glacial acetic acid, the content of each well was mixed and transferred to
210 sterile well plate and this setup was read at 590nm. The test organisms were classified as
211 weakly, moderately adherent, non-adherent and strongly adherent bacteria based on the criteria
212 ($OD < OD_c$ = Non adherent, $OD_c < OD < 2 \times OD_c$ = weakly adherent, $2 \times OD_c < OD < 4 \times OD_c$ =
213 moderately adherent, $4 \times OD_c < OD$ = strongly adherent where OD_c = average OD of negative
214 control [23].

215 **Coating of urinary catheter with AgNPs**

216 Urinary Catheter was segmented to 1×1cm. Catheter pieces were entirely dipped in
217 synthesized AgNPs suspension with different concentration of AgNPs coated catheter such as

218 20 μ g/mL, 40 μ g/mL, 80 μ g/mL, 120 μ g/mL, 160 μ g/mL for 24 h. Excess of suspension was
219 removed by blotting and dried at 50°C [24].

220 **Biofilm inhibition in AgNPs coated catheter**

221 Conical flask containing 25mL of sterile trypticase soy broth inoculated with 100 μ L
222 of mid-log phase pathogenic culture. Two sterile catheters were introduced into the medium
223 using sterile forceps. Different concentration of synthesized AgNPs coated catheter (20 μ g/mL,
224 40 μ g/mL, 80 μ g/mL, 120 μ g/mL, 160 μ g/mL) was introduced into the medium using sterile
225 forceps. Later, this setup was subjected to incubation for 24h at 37 °C. Sterile broth was
226 maintained as negative control. Biofilm control was maintained with pathogen in the growth
227 medium. After incubation, the catheters were removed from broth and transferred into sterile
228 PBS phosphate buffered saline to get rid of planktonic cells and then the catheter was stained
229 with 0.1% crystal violet (CV) for 10 mins. The catheters were dried and observed under
230 compound microscope.

231 Staining solutions were made out by mixing 0.05mL of stock solution of 1% Acridine
232 orange with 5mL of acetate buffer 0.2M (pH4). Sterile catheter was placed with AgNPs treated
233 and untreated bacterial pathogen and allowed to dried at 50°C, the bacterial cells adhered to
234 catheter surface was fixed with absolute methanol and stained with Acridine orange for 1 min,
235 rinsed with distilled water and dried. The catheters were observed for fluorescence microscope
236 [25]. The biofilm can be observed on the surface of the catheter [26].

237 Biofilm inhibition percentage of the urinary catheter coated with AgNPs was studied
238 using microtiter well plate method. 50 μ L of TSB diluted with 10 μ L of mid-log phase culture
239 was added to the wells. Different concentration of AgNPs coated catheter
240 (20 μ g/mL,40 μ g/mL,80 μ g/mL,120 μ g/mL,160 μ g/mL) was added to the respective wells. Test
241 culture with uncoated sterile catheter act as a negative control. The well plates were incubated
242 for 24h at 37 °C [3]. After 24 h incubation, the catheters were removed and washed twice with

243 sterile distilled water to remove the planktonic cells. Catheter containing biofilm was stained
244 with 1mL of 0.4% CV solution and then washed with sterile distilled water to remove excess
245 stain. Stain was then solubilized by 1mL of absolute ethanol. The well plates were read for OD
246 value at 590nm using micro titer plate reader. Conducted experiments were done in triplicate
247 and graph was drawn using graph pad prism version 9.1.2.

248 The inhibition percentage was calculated by the formula

$$249 \quad \frac{(Ab_c - Ab_t)}{Ab_c} \times 100 \quad (2)$$

250 Where Ab_c = absorbance of control well Ab_t = absorbance of test well

251 **Antibacterial activity of AgNPs coated urinary catheter**

252 Antibacterial activity of AgNPs coated catheter was assessed by the following
253 procedure. Each test bacterial strain of 0.5 McFarland standards [19,27] was swabbed on MHA
254 plates using a sterile swab. AgNPs coated catheter and uncoated catheter was situated on agar
255 and incubated at 37 °C for 24 h and zone of inhibition was observed and measured [27].

256 **SEM analysis of urinary catheter**

257 AgNPs coated catheter and uncoated catheter pieces were introduced into trypticase soy
258 broth which is inoculated with a strong biofilm former *E. coli* AMB4, aseptically for 48 h at
259 37 °C. To analyze SEM, catheters were fixed with 2.5% of Glutaraldehyde in 0.1M sodium
260 phosphate buffer for 3 hours and washed with 0.1M sodium phosphate buffer. Then the sample
261 was allowed to dehydrate through a series of ethanol wash: 30%, 50%, 80% for 10 min [21,28].

262 **Result**

263 **Optimization of AgNPs production**

264 Initially the preliminary confirmation of AgNPs production in the reaction mixture
265 through green process was observed through the visual color change followed by surface

266 plasmon resonance (SPR) using UV–visible spectroscopy as a tremendous tool. An intense
267 peak at 410nm by UV–visible absorption spectra confirmed the formation of colloidal AgNPs.
268 *Carissa carandas* leaf extract pH was found to be pH 7 and the UV spectra of the leaf extract
269 was observed as shown in the Fig 1. There is no interesting λ_{\max} peak in *C. carandas* leaf extract
270 and silver nitrate solution as shown in the Fig 1. Optimum reduction of Ag^+ by *C. carandas*
271 leaf extract to attain the maximum AgNPs production was succeeded by modifying the pH,
272 substrate concentration, silver ion concentration, and production time and their wavelength
273 were revealed in Figs 2 (A, B, C and D). In summary, pH is one of the most important variables
274 in nanoparticle products. In acidic environment, particles did not form (pH 2 and 3). At alkaline
275 pH 10, the color production occurred quick, although only weak peak was visible. The reaction
276 was begun as soon as the silver nitrate was introduced to the reaction at neutral pH 7. The
277 solution changed color from pale yellowish to dark brown, indicating the production of silver
278 nanoparticles. Production of AgNPs was further verified by the characteristic absorption peak
279 (Fig 2 A) at 410nm in the UV-visible spectrum. Interestingly a strong intense peak was
280 observed at pH 9 at the same wavelength of 410nm but **the agglomeration of the reaction** was
281 observed.

282 Different concentration of *C. carandas* leaf extract was optimized for maximum
283 production of AgNPs. However, the different extract concentration shows peak at 410nm.
284 Interestingly 10ml of **reaction** mixture containing 1.25mL of leaf extract (Fig 2 B) was turned
285 to dark brown immediately after the addition to 0.1mM of silver nitrate solution at an optimized
286 pH 7.

287 Different concentration of silver nitrate was optimized for the maximum synthesis of
288 AgNPs. 1.25mM concentration of silver nitrate (Fig 2C) shows a strong intense peak at 410nm
289 and the reaction mixture was turned immediately to dark brown after the addition optimized

290 leaf extract of 1.25mL and altering to optimized pH 7. However, 2.0mM, 1.75mM and 1.5mM
291 silver nitrate concentration shows much weaker absorbance peak at 410nm.

292 Time taken for the maximum AgNPs production was optimized by measuring the
293 reaction solution in UV-visible spectroscopy at a various time interval, where the reaction
294 mixture contains optimized silver nitrate concentration of 1.25mM with optimized substrate
295 concentration of 1.25ml at an optimized pH 7. And the dark brown color occurred within
296 20min of incubation, suggesting that AgNPs formed quickly. However, the color change
297 observed in 25 and 30 mins was very dark than the color obtained in 20mins (Fig 2D), the
298 absorbance spectra at 25 and 30 mins showed weak characteristic peak. As a result, the
299 optimized medium enabled for the greatest production of silver nanoparticles, and the reaction
300 took place quickly.

301 **Characterization of nanoparticles**

302 **EDS**

303 Presence of silver element in synthesized AgNPs was confirmed by Energy Dispersive
304 analysis Fig 3 (A). Metallic AgNPs shows a typical optical absorption peak at 3KeV. Peaks of
305 silver element were obtained at 3keV from the particle of *C. carandas* leaf mediated obtained
306 AgNPs. Few weaker peaks were observed which corresponding to O and C also found.

307 **XRD**

308 XRD pattern was evaluated to resolve the width, peak position and peak intensity in 2 θ
309 spectrum ranging from 20° to 80° as depicted in Fig 3 (B). Characteristic peaks at 38.01, 44.13,
310 64.46, 77.40; Bragg reflections corresponding to [111], [200], [220] and [311] lattice plans of
311 FCC structure (JCPDS File No. 04–0783) of AgNPs were observed. This pattern shows the
312 crystalline structure of AgNPs, size of AgNPs was calculated by full width at half-maximum
313 (FWHM) data with the Scherrer formula $D = K \lambda / \beta \cos \theta$ was estimated to be 25.4 nm. Where

314 $k = \text{constant}$, $\lambda = \text{X-ray wavelength}$, $\beta = \text{angular FWHM}$, $\theta = \text{Braggs diffraction angle}$ and $D =$
315 crystalline size of diffraction angle θ .

316 In addition, three unassigned peaks appeared at 27.99° , 32.13° and 46.28° . These peaks were
317 weaker than those of silver. This may be due to the bioorganic compounds occurring on the
318 surface of AgNPs. Appearances of these peaks are due to the presence of phytochemical
319 compounds in the leaf extracts. The stronger planes indicate silver as a major constituent in the
320 biosynthesis.

321 **FTIR**

322 The FTIR spectrum of AgNPs shows major absorption band around 440.02, 479.57,
323 548.00, 1104.68, 1383.22, 1443.38, 1621.55, 2921.60, 3419.99 cm^{-1} and the crude *C. carandas*
324 leaf extract shows absorption spectra on 780.44, 1105.57, 1315.55, 1386.44, 1443.56, 1617.79,
325 2922.97, 3421.32 cm^{-1} depicted in Fig 4 (D). The peak on 440.02 was due to aryl disulphide
326 stretches, 479.57 cm^{-1} was due to polysulphide stretches, 548 due to C-I stretches and 1104.68
327 and 1105.57 were $-\text{C}-\text{O}-$ stretching vibration of alcohol and phenol, 1443.38 and 1443.56 cm^{-1}
328 were $-\text{C}=\text{C}-$ aromatic structures, 1621.55 and 1617.79 were the $-\text{C}=\text{C}-$ alkene group. Peaks
329 2921.60, and 2922.97 cm^{-1} were $-\text{CHsp}^3$ group and the band on 3419.99 and 3421.32 cm^{-1} were
330 the normal polymeric stretch of hydroxyl (OH) group. The absorption band is due to the
331 vibration effect of the alkaloids, terpenoids and flavonoids present in the plant extract and plays
332 crucial role in capping and stabilization of AgNPs. The band shift of hydroxyl group in the
333 FTIR spectra confirmed the binding of Ag^+ to the OH group. All the changes in peak support
334 the impact of functional group in *C. carandas* leaf extract as reducing and stabilizing agents to
335 synthesize AgNPs. Some peaks appeared in the FTIR spectrum of leaf and disappeared in
336 AgNPs spectrum. The disappearance of peaks suggests that phytochemical present in the
337 extract involved in the reduction of AgNPs [29].

338

339 **HR-TEM**

340 High resolution Transmission electron microscope determined the morphology, shape
341 and size of bio fabricated AgNPs as shown in the Fig 4 (A). we have analyzed TEM micrograph
342 using Image J software and from the analysis we have found the particles was polydispersed
343 and predominantly found to be spherical with the average diameter of approximately 14nm
344 were determined through the histogram obtained Fig 4 (B). SAED pattern image of AgNPs
345 revealed the diffraction rings from inside to outside, could be indexed as [111, 200, 220, 311]
346 reflections respectively with some bright spots due to Bragg's reflection, corresponding to face-
347 centered cubic (fcc) silver was depicted in Fig 4 (C).

348 **Antibacterial activity**

349 Antibacterial activity of synthesized AgNPs was evaluated against Gram positive and Gram
350 negative uropathogens such as *S. aureus*, *E. coli* and *P. aeruginosa*. The clear zone was
351 gradually increased based on the dose dependent manner as shown in the Table 1 and Fig 5.
352 The well diffusion assay also performed for comparative study of crude extract, AgNO₃
353 solution, Standard antibiotic Ciprofloxacin (50µg/mL), AgNPs, DMSO as a solvent control as
354 shown in Fig. 6 and these results were depicted in the Table 2.

355 **Minimum Inhibitory (MIC) and Minimum Bactericidal**

356 **Concentration (MBC)**

357 After 24 h of incubation at 37°C, turbidity was noticed in the *E. coli* AMB4 well plates
358 20 and 40 µg/mL containing silver nanoparticles indicating the growth of bacteria. Whereas in
359 the concentrations of 60, 80, 100, 120, 140, 160 µg/mL, no turbidity was seen, indicating the
360 inhibition of bacterial growth (Fig 7). Highest concentration 160 µg/mL of AgNPs, OD_{590nm}
361 (0.18) shows 99% inhibition, whereas the minimum inhibitory concentration was found to be
362 60 µg/mL, OD_{590nm} (0.63) shows 97% inhibition towards *E. coli* AMB4. The MHA plates also

363 show no bacterial growth from the concentrations of 60, 80, 100, 120, 140, 160 µg/mL, hence
364 confirming it as bactericidal.

365 Similarly, *S. aureus* AMB6 and *P. aeruginosa* AMB5 well plate containing AgNPs
366 showed turbidity in 20 µg/mL, whereas no turbidity was seen in the concentrations of 40, 60,
367 80, 100, 120, 140, 160 µg/mL containing AgNPs indicating the bacterial inhibition (Fig 7).
368 Highest concentration 160 µg/mL of AgNPs, OD_{590nm} (0.22) shows 99% inhibition for *S.*
369 *aureus* AMB6 and highest concentration 160 µg/mL of AgNPs, OD_{590nm} (0.25) shows 99.5%
370 inhibition for *Pseudomonas aeruginosa* AMB5. Therefore, MIC of *S. aureus* AMB6 was found
371 to be 40 µg/mL with OD_{590nm} (0.69) shows 97% inhibition and MIC of *P. aeruginosa* AMB5
372 was found to be 40 µg/mL, OD_{590nm} (0.60) shows 97% inhibition. The MHA plates also show
373 no bacterial growth from the concentrations of 40, 60, 80, 100, 120, 140, 160 µg/mL, hence
374 confirming it as bactericidal.

375 **Synergistic effect of silver nanoparticles with commercial** 376 **antibiotics**

377 In the present work, 3 commercial antibiotics were tested alone and with AgNPs against
378 the test pathogens. AgNPs alone showed antimicrobial activity and commercial antibiotics also
379 showed antimicrobial activity when the AgNPs is combined with the commercial antibiotics,
380 the antimicrobial activity increased with increased fold as it was evidenced in Table.3.
381 Maximum increase in fold area was 3.84 and 2.3 against trimethoprim (Table 3). The
382 synergistic antimicrobial activity against *P. aeruginosa* was better than that of *E. coli* and *S.*
383 *aureus*. Maximum increase in fold was 3.84 against trimethoprim 1.04 for *E. coli* while it was
384 2.3 for *S. aureus* against trimethoprim (Table 3)

385

386

387 **Bacterial biofilm potential**

388 In our study, the biofilm forming ability was verified by test tube method. The test tube
389 base contains the adhered layer of uropathogens. *P. aeruginosa* forms a strong biofilm mat than
390 another organism. The biofilms were analyzed quantitatively to check the potential biofilm
391 formers, *P. aeruginosa* shows $OD_C (0.1784) < OD (3.045)$ however *S. aureus* also produce
392 strongly adherent biofilm layer $OD_C (0.1784) < OD (3.1074)$, *E. coli* shows an $OD_C (0.1784)$
393 $< OD (3.012)$ confirms that it is a strong biofilm former.

394 **Biofilm inhibition in AgNPs coated catheter**

395 AgNPs coated catheter (Fig 8) was evaluated for the anti-biofilm activity against the
396 uropathogens. Uropathogens adhered to the surface of catheter was treated with different
397 concentration of AgNPs and subjected to microscopic analysis. Under the microscopic
398 observation tightly adhered cells are gradually dispersed depending upon the concentration of
399 NPs compare whereas control showed an adhered mat formation as shown in S1 Fig. Viability
400 and disruption of biofilm mat after AgNPs treatment was analyzed by fluorescence microscopy,
401 showed an abruption of biofilm on AgNPs coated catheters as shown in S2 Fig. Dense biofilm
402 mat on uncoated catheter using an acridine orange staining method. In quantitative assay,
403 highest concentration of AgNPs coated catheter showed the highest level of inhibition. The
404 inhibition of *Pseudomonas aeruginosa* $85.8 \pm 1.450\%$ was slightly higher than the *S. aureus*
405 $82.8 \pm 1.83\%$ whereas the inhibition percentage of *E. coli* $71.4 \pm 1.25\%$ become lesser than the
406 other two test pathogen. Percentage of inhibition was calculated and shown in Fig. 9.

407 **Antibacterial activity of AgNPs coated urinary catheter**

408 Antibacterial activity of AgNPs coated urinary catheter and uncoated catheter as shown
409 in the Fig.8 was evaluated where $40\mu\text{g/mL}$ of AgNPs coated catheter exhibits antibacterial
410 activity with the value of 17 ± 0.4 , 21 ± 0.3 , and 13 ± 0.1 for *S. aureus* AMB6, *E. coli* AMB4, and

411 *P. aeruginosa* AMB 5, respectively. Urinary catheter impregnated with AgNPs shows ZOI
412 against uropathogens whereas uncoated catheter shows no zone of inhibition (Table 2).

413 **SEM analysis of Urinary catheter**

414 SEM analysis of AgNPs coated catheter Fig. 10 (A) clearly shows the strong overlaying of
415 AgNPs on the catheter surface and uncoated catheter Fig 10 (B) shows a clear image of catheter
416 surface. Further, SEM imaging was done on the AgNPs coated catheter inoculated with strong
417 biofilm former *E. coli* AMB4 Fig 10 (D) states the biofilm mat formed by the *E. coli* AMB4
418 was disturbed due to the activity of AgNPs and Fig 10 (C) clearly shows the dense biofilm mat
419 on the surface of the uncoated catheter inoculated with *E. coli* AMB4 which proves that *E. coli*
420 AMB4 is a strong biofilm former. Incorporation of urinary catheter (biomedical devices) with
421 AgNPs provide better biocompatibility.

422 **Discussions**

423 Uropathogens are the major cause of UTI with their biofilm formation. These
424 uropathogens are notorious and perpetuating. They become combat against wide range of
425 antibiotics and environmental stress such as host immune response. They are difficult to treat
426 and eradicate [30]. The major toughness of biofilm is architecture EPS, quorum sensing (QS)
427 activity. The over production of EPS leads to resistant against antibiotic and another crucial
428 factor is QS (construction of wild type architecture) it increases the stability against oxidative
429 and osmotic stresses of biocide [31] Milan et al. [32] states that nosocomial acquired UTI
430 shows high level of resistant than community acquired UTI show the patient indwelling
431 catheters shows high risk of UTI. Due to its biocompatibility and backdrop of antimicrobial
432 resistant create the thirst of seeking naive therapeutic despite of antibiotic [33]. The plant
433 derived drug compiled with nanotechnology wrap out the resistance against Uropathogens. In
434 this present study, *C. carandas* leaf extract was subjected to synthesize silver nanoparticle,

435 with potent antibacterial and antibiofilm activity. The choice of green synthesis of NPs was
436 due to their capping capability and stability. Biosynthesized NPs are facile; cost of effective,
437 fast, non-toxic, possessing well defined morphology and uniformity in size [34]. Ag⁺ capped
438 with the phytomolecules present in the plant enhanced the antimicrobial activity. Fig 2 (A-D)
439 demonstrates the absorption spectra of SPR for the optimization of AgNPs synthesis under
440 distinct parameters viz. pH, crude extract concentration, Ag ion concentration and incubation
441 time for analysis. These results provide for evaluating the reaction parameter and optimized
442 conditions for NPs synthesis [35] Ibrahim [36] stated that, reaction mixture color and SPR
443 intensity which are pH dependent.

444 In our study, acidic and alkaline pH shows weak absorbance peak. However, strong
445 intense peak was observed in pH 9, agglomeration of reaction was happened. The neutral pH
446 7 typically increased the absorbance peak and provide a favorable environment. Crude
447 concentration is noteworthy due to their phytochemical stabilizing agents. The raising of
448 absorption peak was noticed in in 1.25ml of extract concentration. Whereas the addition of
449 higher crude concentration lead to decreased absorbance peak [37]. The absorption peaks were
450 gradually increased with the increased metal concentration which may be attributed by
451 longitudinal vibrations [38]. **Optimized parameters of AgNPs have** 1.25mM concentration of
452 AgNO₃, 1.25mL of substrate concentration with pH7 supported the maximum formation of
453 AgNPs within 20 minutes time period. The color change of the heterogeneous reaction mixture
454 observed at 410nm due to their electron excitation similar observation [39]. FTIR peak of our
455 study was in accordance to Pavia et al. 2009 [40], the peaks ranging from 3200-3600 cm⁻¹ are
456 related to the O-H and -NH₂ stretching vibrations and suggest that hydroxyl and carbonyl
457 groups may responsible for the synthesis and stabilization of AgNPs [41], the peak at 2921.60
458 and 2922.97 are assigned to C-H stretching [40]. According to Mariselvam et al. [42]
459 absorption band ranging from 1700-1600 cm⁻¹ in the spectra confirms the formation of AgNPs.

460 The bands observed at 1383.22 cm^{-1} and 1386.44 cm^{-1} corresponds to the C-N stretching
461 vibration of aromatic amine [43]. The presence of amines or alcohols or phenols represents the
462 polyphenols capped by AgNPs [44,45]. The shifting peak up and down reveals the synthesis
463 of AgNPs. Biomolecules in *C. carandas* leaf extract is responsible for the stabilization of
464 AgNPs [46]. The FTIR analysis speaks the stretch band and bond of AgNPs, the presence of
465 potential biomolecules with Ag attachment leads stabilization and capping [3,19]. Due to their
466 surface adhered potential biomolecules, green mediated AgNPs shows the higher anti-bacterial
467 and anti-biofilm activity [47]. The size and shape of AgNPs plays a major role in bactericidal
468 activity [48]. XRD analysis revealed the crystalline nature of AgNPs presence of silver
469 confirmed by the diffraction pattern. These XRD patterns reported in earlier studies Saratale et
470 al. [49] was accordance with our results. EDX profile outcomes exhibits the strong signal for
471 silver approximately at 3KeV due to the SPR which is identical to Ramar et al. [50] and
472 Magudapathy et al. [51] for the production of leaf extract mediated synthesis AgNPs. The
473 structure and size of NPs were concluded as spherical and polydispersed with the approximate
474 size of 14nm was confirmed by HR-TEM analysis [52]. SAED pattern of AgNPs was shown
475 in the Fig 4C. Further ring like diffraction pattern indicates that the particles are crystalline
476 [53]. During recent years, undesirable consequence effect of catheter related UTI infections
477 lead to the increased mortality [54]. Application of AgNPs shows the efficient antimicrobial
478 activity and that are justifiable tool for evading indwelling catheter related infections.
479 Medically implantable devices coated with AgNPs which are requisite factor for evading the
480 bacterial adherence and agglomeration of biofilm [55] in this investigation reported that, *E.*
481 *coli* (71.4%), *S. aureus* (82.8%), *P. aeruginosa* (85.8%) these nosocomial clinical pathogens
482 are prevalent in formation of biofilm. These results were similar to Sharma et al. [56] and
483 Kamarudheen and Rao [57]. The AgNPs embedded catheter shows antimicrobial activity
484 against uropathogens which may due to their size and inhibition capacity that makes the drug

485 resistant uropathogens susceptible [58]. The commercial catheters coated with AgNPs (Fig 8)
486 creates the efficiency against the UTI. Urinary catheters are the major cause of biofilm
487 formation in urinary tract results in nosocomial infection [59]. Techniques followed to coat
488 urinary catheter as layer by layer for enzyme coating, impregnation of antimicrobial agents
489 [60], polycationic nanosphere coating [61], impregnation of complex molecules [62]. In recent
490 years, impregnation of urinary catheter with silver is under practice [63]. AgNPs is a fast and
491 promising strategy for bactericidal coating on silicone based medical devices [64]. In recent
492 years, there is rise in mortality rate associated with catheter associated urinary tract infection
493 [65]. Therefore, it is important to coat the medical devices with antimicrobial agents. AgNPs
494 are excellent tool for avoiding catheter associated UTI [55]. The solid surface provides a strong
495 anchoring habitation for bacteria to form biofilm, similarly biofilm is formed on the surface of
496 implant device, which protects the bacteria from antibiotic action and cause several infections
497 [66]. Additionally, functionalized, immobilized and surface modified AgNPs embedded on
498 surface of implants are inhibiting bacterial adhesion and *icaAD* transcription in implants [67].

499 The AgNPs reduces the encrustation of obstinate biofilm and ruptures and disintegrate
500 the biofilm mat and shows bactericidal activity against uropathogens. The coated catheter
501 shows antibacterial, anti-EPS and anti-quorum sensing activity of uropathogens and end up the
502 pathogens into avirulent and disrupt the biofilm [68]. Fluorescence microscopy (S₂ Fig.) shows
503 the bacterial biofilm formation over uncoated urinary catheter by uropathogens whereas
504 biofilm disruption was observed in the AgNPs coated urinary catheter exposed to
505 uropathogens. Differentiation of live and dead cells was exhibited by fluorescence with
506 intercalation of Acridine orange[69]. AgNPs are responsible for the anti-cancer, anti-oxidant,
507 anti-microbial activity. The *in-vitro* studies show efficient result against uropathogens by using
508 AgNPs coated catheters. Scanning Electron Microscopy (Fig 10) was employed to identify the

509 biofilm formation and destruction in surface modified and unmodified catheters using AgNPs
510 exposed to uropathogens.

511 The AgNPs have tremendous advantage for biological applications over the bulk metal
512 owing to its size that enables the NPs to facilitate to anchor in to the micro cell (bacteria)
513 components [70]. AgNPs causes physical damage to the cell components leads to killing of
514 bacteria (Fig 11). Because of the cell wall, architecture, thickness varies, AgNPs antibacterial
515 action is associated with gram positive and gram-negative bacteria [71]. Plenty of hypothesis
516 that have been proposed, the antibacterial mechanism action has yet to be definitively
517 established. The antibacterial mechanism (Fig 11) that we postulated based on the existing
518 literature may be described as follows; 1) plant mediated AgNPs adherence to the membrane
519 of cell forms an electrostatic interaction results in the leakage of internal substances; 2) Ag⁺
520 ions or AgNPs interact with the sulfhydryl group of enzymes and proteins [72] and inhibit the
521 enzymatic and protein activity; 3) Cellular toxicity induced by AgNPs is triggered by reactive
522 oxygen species (ROS) and free radicals, which destroys internal organelles and causes cell
523 death, lipid peroxidation, and DNA damage ; 4) AgNPs interact with the ribosome and inhibit
524 the translation process in the cell. The high surface area of AgNPs in generating silver ions
525 explain the mechanism of AgNPs action. In the presence of oxygen and proton, aqueous AgNPs
526 were oxidized producing silver ions when the particle dissolves [73]. The toxicity of smaller
527 or anisotropic AgNPs with greater surface area was higher [74]. For improved antibacterial
528 action, the greatest concentration of silver ions, quickest release of silver ions and greater
529 surface area of silver ions are evaluated [75]. AgNPs antibacterial action is mostly owing to
530 their capacity to generate ROS and free radical [76]. These free radicals attached to the cell
531 wall of bacteria and generate pore, these pores ultimately cause cell death [77]. Moreover,
532 production free radical and high levels of reactive oxygen species (ROS) are also a precise
533 mechanism of AgNPs to inhibit bacterial by apoptosis and DNA damage [78]. There are

534 different proposed mechanisms for antimicrobial activity of AgNPs. AgNPs (positively
535 charged) can easily interact with negatively charged cell membrane which enhances the
536 antibacterial activity [79]. The charges in the cell can facilitate the attraction of AgNPs for
537 attachment on to the cell membrane [80]. AgNPs also destabilize the ribosomes, **mitochondrial**
538 dysfunction and inhibit the electron transport chain [67]. AgNPs causes damages to bacteria
539 by interfering the function of DNA replication [81], cell division and respiratory chain [82].
540 Because of the combination of cell wall components and AgNPs charges, the effect of AgNPs
541 on gram positive bacteria is smaller than on gram negative bacteria [67]. The killing of bacteria
542 directed through several phenomenon like penetration of AgNPs in to membrane, surface area
543 in contact, reach cytoplasm, ribosomes, interaction with cellular structures and biomolecules
544 by several process [73].

545 **Our study proposed the antibiofilm mechanism (Fig 12) of AgNPs** can be summarized
546 as follows: 1) AgNPs has electrostatic interaction with the cells and disturb the biofilm
547 formation; 2) AgNPs degrade the EPS formation and breaks the biofilm mat; 3) AgNPs inhibits
548 the signal produced by the bacteria, thereby inhibiting the biofilm formation; 4) AgNPs
549 penetrate the biofilm and creates anti-adherence which ultimately cause the leakage of cellular
550 contents. **Bacterial adhesion, biofilm development and biofilm integrity, as well as internal**
551 **communication, are all aided by extracellular DNA (eDNA) [83]. eDNA acts as an excellent**
552 **target to eliminate bacterial biofilm [84]. eDNA is polyanionic nature and electrostatic contact**
553 **is mostly mediated by AgNPs that are positively charged. Through short range hydrophobic**
554 **and Vander Waals force, silver ions interact with the oxygen and nitrogen atoms of DNA bases**
555 **[85-87]. Electrostatic interaction, on the other hand, has an impact on them. In biofilms, AgNPs**
556 **interact with both cellular and extracellular RNA [88,89]. Studies shows that AgNPs interact**
557 **with the small regulatory RNA, reduced biofilm and fibronectin binding by altering the RNA**
558 **profile of S. aureus [88]. Earlier, several reports on antibiofilm activity of AgNPs against**

559 several bacteria shows a promising activity [67] [90,91]. Among all AgNPs interactions,
560 AgNPs with *Pseudomonas putida* shows an innovative finding to arrest biofilm [67,90,91].
561 Extracellular proteins are the essential component of biofilm. AgNPs interact with these protein
562 and extracellular polysaccharide secreted in biofilm [92]. Several studies shows that AgNPs
563 reduced the synthesis of extra polysaccharides in *P. aeruginosa* and *S. epidermidis* biofilm and
564 their mechanism was unknown [93].

565 The leaf extract of *C. carandas* is said to contain a lot of flavonoids [16]. AgNPs
566 synthesized using *C. carandas* leaf extract showed antibacterial activity [94]. The mechanism
567 for AgNPs synthesis includes; silver ions have positive charge that attracts the functional group
568 of phytochemicals found in plants. The phytochemicals such as flavonoids, alcoholic and
569 phenolic compounds, tannins, terpenoids, glycosides act as a reducing agent and reducing Ag⁺
570 ion to Ag⁰ [95].

571 Hence, an overall mechanism proposed that phytochemical mediated synthesized
572 AgNPs will open a new avenue to use as antibacterial and antibiofilm candidate after
573 embedding in to implants.

574 **Conclusion**

575 Even though, many literatures were available for silver nanoparticles, silver is gaining
576 its attention because of its antimicrobial properties. Synthesis of AgNPs using the leaf extract
577 will provide an ecofriendly, cheap, easily available and non-toxic. In the present study, green
578 synthesis of AgNPs was done using *C. carandas* leaf extract, AgNPs exhibited excellent
579 antibacterial activity towards *S. aureus* AMB6 and also showed excellent synergistic activities
580 against *P. aeruginosa* AMB 5, AgNPs coated urinary catheter showed highest biofilm
581 inhibition in *Pseudomonas aeruginosa* AMB5 $85.8 \pm 1.450\%$. The potential of AgNPs in
582 inhibiting the biofilm formation supports it as a potential application for AgNPs coated medical
583 devices. Thus, the present study helps in disclosing the biomaterial coating acts as a preventive

584 shield against uropathogens and it is long lasting, feasible technique and it act as promising
585 treatment for UTI and nosocomial infections.

586 **Conflicts of interest**

587 The authors have no conflicts of interest to declare. All co-authors have seen and agree with
588 the contents of the manuscript and there is no financial interest to report.

589 **Authors Contributions**

590 PV came up with the idea and participated in the design, preparation of AgNPs, and writing of
591 the manuscript. HBHR performed the characterization of nanoparticles. RD participated in
592 culturing, antibacterial activity, anti-biofilm activity, and other biochemical assays. TS, SM
593 and RP participated in the coordination of this study. All authors read and approved the final
594 manuscript.

595 **Acknowledgements**

596 The authors thank the Vice-Chancellor and Registrar of Alagappa University for providing the
597 research facilities.

598 **Reference:**

- 599 1. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and
600 economic costs. *The American journal of medicine* 113: 5-13.
- 601 2. Nicolle LE, Yoshikawa TT (2000) Urinary tract infection in long-term-care facility residents.
602 *Clinical infectious diseases* 31: 757-761.
- 603 3. Divya M, Kiran GS, Hassan S, Selvin J (2019) Biogenic synthesis and effect of silver
604 nanoparticles (AgNPs) to combat catheter-related urinary tract infections. *Biocatalysis*
605 and agricultural biotechnology 18: 101037.

- 606 4. Sileika TS, Kim H-D, Maniak P, Messersmith PB (2011) Antibacterial performance of
607 polydopamine-modified polymer surfaces containing passive and active components.
608 ACS applied materials & interfaces 3: 4602-4610.
- 609 5. Siddiq DM, Darouiche RO (2012) New strategies to prevent catheter-associated urinary tract
610 infections. Nature Reviews Urology 9: 305-314.
- 611 6. Warren JW (1997) Catheter-associated urinary tract infections. Infectious disease clinics of
612 North America 11: 609-622.
- 613 7. Doll K, Jongstaphongpun KL, Stumpp NS, Winkel A, Stiesch M (2016) Quantifying
614 implant-associated biofilms: Comparison of microscopic, microbiologic and
615 biochemical methods. Journal of microbiological methods 130: 61-68.
- 616 8. Singha P, Locklin J, Handa H (2017) A review of the recent advances in antimicrobial
617 coatings for urinary catheters. Acta biomaterialia 50: 20-40.
- 618 9. Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, et al. (2016) Biofilms: an
619 emergent form of bacterial life. Nature Reviews Microbiology 14: 563-575.
- 620 10. Geetha AR, George E, Srinivasan A, Shaik J (2013) Optimization of green synthesis of
621 silver nanoparticles from leaf extracts of *Pimenta dioica* (Allspice). The Scientific
622 World Journal 2013.
- 623 11. Devi JS, Bhimba BV, Ratnam K (2012) In vitro anticancer activity of silver nanoparticles
624 synthesized using the extract of *Gelidiella* sp. Int J Pharm Pharm Sci 4: 710-715.
- 625 12. Rai M, Ingle AP, Gade A, Duran N (2015) Synthesis of silver nanoparticles by *Phoma*
626 *gardeniae* and in vitro evaluation of their efficacy against human disease- causing
627 bacteria and fungi. IET nanobiotechnology 9: 71-75.
- 628 13. Morton JF (1987) Fruits of warm climates: JF Morton.

- 629 14. Verma K, Shrivastava D, Kumar G (2015) Antioxidant activity and DNA damage inhibition
630 in vitro by a methanolic extract of *Carissa carandas* (Apocynaceae) leaves. Journal of
631 Taibah University for Science 9: 34-40.
- 632 15. Verma S, Chaudhary H (2011) Effect of *Carissa carandas* against clinically pathogenic
633 bacterial strains. Journal of Pharmacy Research 4: 3769.
- 634 16. Sawant RS, Godghate A (2013) Comparative studies of phytochemical screening of *Carissa*
635 *carandus* Linn. Asian J Plant Sci Res 3: 21-25.
- 636 17. Pathak G, Singh S, Singhal M, Singh J, Hussain Y, et al. (2021) Pharmacology of *Carissa*
637 *carandas* leaf extract: anti-proliferative, antioxidant and antimicrobial investigation.
638 Plant Biosystems-An International Journal Dealing with all Aspects of Plant Biology
639 155: 543-556.
- 640 18. Agarwal T, Singh R, Shukla AD, Waris I (2012) In vitro study of antibacterial activity of
641 *Carissa carandas* leaf extracts. Asian J Plant Sci Res 2: 36-40.
- 642 19. Kora AJ, Sashidhar R, Arunachalam J (2010) Gum kondagogu (*Cochlospermum*
643 *gossypium*): a template for the green synthesis and stabilization of silver nanoparticles
644 with antibacterial application. Carbohydrate Polymers 82: 670-679.
- 645 20. Parvekar P, Palaskar J, Metgud S, Maria R, Dutta S (2020) The minimum inhibitory
646 concentration (MIC) and minimum bactericidal concentration (MBC) of silver
647 nanoparticles against *Staphylococcus aureus*. Biomaterial Investigations in Dentistry 7:
648 105-109.
- 649 21. Agarwala M, Barman T, Gogoi D, Choudhury B, Pal AR, et al. (2014) Highly effective
650 antibiofilm coating of silver-polymer nanocomposite on polymeric medical devices
651 deposited by one step plasma process. Journal of Biomedical Materials Research Part
652 B: Applied Biomaterials 102: 1223-1235.

- 653 22. Christensen GD, Simpson WA, Younger J, Baddour L, Barrett F, et al. (1985) Adherence
654 of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model
655 for the adherence of staphylococci to medical devices. *Journal of clinical microbiology*
656 22: 996-1006.
- 657 23. Saxena S, Banerjee G, Garg R, Singh M (2014) Comparative study of biofilm formation in
658 *Pseudomonas aeruginosa* isolates from patients of lower respiratory tract infection.
659 *Journal of clinical and diagnostic research: JCDR* 8: DC09.
- 660 24. Thomas R, Soumya K, Mathew J, Radhakrishnan E (2015) Inhibitory effect of silver
661 nanoparticle fabricated urinary catheter on colonization efficiency of Coagulase
662 Negative Staphylococci. *Journal of Photochemistry and Photobiology B: Biology* 149:
663 68-77.
- 664 25. Merritt JH, Kadouri DE, O'Toole GA (2006) Growing and analyzing static biofilms.
665 *Current protocols in microbiology*: 1B. 1.1-1B. 1.17.
- 666 26. Cady NC, McKean KA, Behnke J, Kubec R, Mosier AP, et al. (2012) Inhibition of biofilm
667 formation, quorum sensing and infection in *Pseudomonas aeruginosa* by natural
668 products-inspired organosulfur compounds. *PLoS One* 7: e38492.
- 669 27. Dhas TS, Kumar VG, Karthick V, Angel KJ, Govindaraju K (2014) Facile synthesis of
670 silver chloride nanoparticles using marine alga and its antibacterial efficacy.
671 *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 120: 416-420.
- 672 28. Djeribi R, Bouchloukh W, Jouenne T, Menea B (2012) Characterization of bacterial
673 biofilms formed on urinary catheters. *American journal of infection control* 40: 854-
674 859.
- 675 29. Anandalakshmi K, Venugobal J (2017) Green synthesis and characterization of silver
676 nanoparticles using *Vitex negundo* (Karu Nochchi) leaf extract and its antibacterial
677 activity. *Med Chem* 7: 218-225.

- 678 30. Høiby N, Ciofu O, Bjarnsholt T (2010) *Pseudomonas aeruginosa* biofilms in cystic fibrosis.
679 Future microbiology 5: 1663-1674.
- 680 31. Wai SN, Mizunoe Y, Takade A, Kawabata S-I, Yoshida S-I (1998) *Vibrio cholerae* O1
681 strain TSI-4 produces the exopolysaccharide materials that determine colony
682 morphology, stress resistance, and biofilm formation. Applied and environmental
683 microbiology 64: 3648-3655.
- 684 32. Milan PB, Ivan IM (2009) Catheter-associated and nosocomial urinary tract infections:
685 antibiotic resistance and influence on commonly used antimicrobial therapy.
686 International urology and nephrology 41: 461.
- 687 33. Gurunathan S, Park JH, Han JW, Kim J-H (2015) Comparative assessment of the apoptotic
688 potential of silver nanoparticles synthesized by *Bacillus tequilensis* and *Calocybe*
689 *indica* in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer
690 therapy. International journal of nanomedicine 10: 4203.
- 691 34. Ahmed S, Ahmad M, Swami BL, Ikram S (2016) A review on plants extract mediated
692 synthesis of silver nanoparticles for antimicrobial applications: a green expertise.
693 Journal of advanced research 7: 17-28.
- 694 35. Ahmed S, Saifullah, Ahmad M, Swami BL, Ikram S (2016) Green synthesis of silver
695 nanoparticles using *Azadirachta indica* aqueous leaf extract. Journal of radiation
696 research and applied sciences 9: 1-7.
- 697 36. Ibrahim HM (2015) Green synthesis and characterization of silver nanoparticles using
698 banana peel extract and their antimicrobial activity against representative
699 microorganisms. Journal of Radiation Research and Applied Sciences 8: 265-275.
- 700 37. Kalpana D, Han JH, Park WS, Lee SM, Wahab R, et al. (2019) Green biosynthesis of silver
701 nanoparticles using *Torreya nucifera* and their antibacterial activity. Arabian Journal of
702 Chemistry 12: 1722-1732.

- 703 38. Prathna T, Chandrasekaran N, Raichur AM, Mukherjee A (2011) Biomimetic synthesis of
704 silver nanoparticles by Citrus limon (lemon) aqueous extract and theoretical prediction
705 of particle size. *Colloids and Surfaces B: Biointerfaces* 82: 152-159.
- 706 39. Medda S, Hajra A, Dey U, Bose P, Mondal NK (2015) Biosynthesis of silver nanoparticles
707 from Aloe vera leaf extract and antifungal activity against *Rhizopus* sp. and *Aspergillus*
708 sp. *Applied Nanoscience* 5: 875-880.
- 709 40. Pavia DL, Lampman GM, Kriz GS, Vyvyan J (2009) *Introduction to Spectroscopy*, Brooks.
710 Cole Cengage Learning: 381-417.
- 711 41. Mohanta YK, Biswas K, Jena SK, Hashem A, Abd_Allah EF, et al. (2020) Anti-biofilm
712 and antibacterial activities of silver nanoparticles synthesized by the reducing activity
713 of phytoconstituents present in the Indian medicinal plants. *Frontiers in Microbiology*
714 11: 1143.
- 715 42. Mariselvam R, Ranjitsingh A, Nanthini AUR, Kalirajan K, Padmalatha C, et al. (2014)
716 Green synthesis of silver nanoparticles from the extract of the inflorescence of *Cocos*
717 *nucifera* (Family: *Arecaceae*) for enhanced antibacterial activity. *Spectrochimica Acta*
718 *Part A: Molecular and Biomolecular Spectroscopy* 129: 537-541.
- 719 43. Vigneshwaran N, Ashtaputre N, Varadarajan P, Nachane R, Paralikal K, et al. (2007)
720 Biological synthesis of silver nanoparticles using the fungus *Aspergillus flavus*.
721 *Materials letters* 61: 1413-1418.
- 722 44. Vanaja M, Annadurai G (2013) *Coleus aromaticus* leaf extract mediated synthesis of silver
723 nanoparticles and its bactericidal activity. *Applied nanoscience* 3: 217-223.
- 724 45. Shah M, Nawaz S, Jan H, Uddin N, Ali A, et al. (2020) Synthesis of bio-mediated silver
725 nanoparticles from *Silybum marianum* and their biological and clinical activities.
726 *Materials Science and Engineering: C* 112: 110889.

- 727 46. Ahmad N, Sharma S (2012) Green synthesis of silver nanoparticles using extracts of
728 *Ananas comosus*.
- 729 47. Singh P, Kim Y-J, Zhang D, Yang D-C (2016) Biological synthesis of nanoparticles from
730 plants and microorganisms. *Trends in biotechnology* 34: 588-599.
- 731 48. Leuck A-M, Johnson JR, Hunt MA, Dhody K, Kazempour K, et al. (2015) Safety and
732 efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-
733 associated bacteriuria: a pilot randomized clinical trial. *American journal of infection
734 control* 43: 260-265.
- 735 49. Saratale RG, Benelli G, Kumar G, Kim DS, Saratale GD (2018) Bio-fabrication of silver
736 nanoparticles using the leaf extract of an ancient herbal medicine, dandelion
737 (*Taraxacum officinale*), evaluation of their antioxidant, anticancer potential, and
738 antimicrobial activity against phytopathogens. *Environmental Science and Pollution
739 Research* 25: 10392-10406.
- 740 50. Ramar M, Manikandan B, Marimuthu PN, Raman T, Mahalingam A, et al. (2015) Synthesis
741 of silver nanoparticles using *Solanum trilobatum* fruits extract and its antibacterial,
742 cytotoxic activity against human breast cancer cell line MCF 7. *Spectrochimica Acta
743 Part A: Molecular and Biomolecular Spectroscopy* 140: 223-228.
- 744 51. Magudapathy P, Gangopadhyay P, Panigrahi B, Nair K, Dhara S (2001) Electrical transport
745 studies of Ag nanoclusters embedded in glass matrix. *Physica B: Condensed Matter*
746 299: 142-146.
- 747 52. Ingle A, Rai M, Gade A, Bawaskar M (2009) *Fusarium solani*: a novel biological agent for
748 the extracellular synthesis of silver nanoparticles. *Journal of Nanoparticle Research* 11:
749 2079-2085.

- 750 53. Ahmad N, Sharma S, Alam MK, Singh V, Shamsi S, et al. (2010) Rapid synthesis of silver
751 nanoparticles using dried medicinal plant of basil. *Colloids and Surfaces B:*
752 *Biointerfaces* 81: 81-86.
- 753 54. Nicolle LE (2012) Urinary catheter-associated infections. *Infectious Disease Clinics* 26:
754 13-27.
- 755 55. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, et al. (2005) The bactericidal
756 effect of silver nanoparticles. *Nanotechnology* 16: 2346.
- 757 56. Sharma M, Yadav S, Chaudhary U (2009) Biofilm production in uropathogenic *Escherichia*
758 *coli*. *Indian Journal of Pathology and Microbiology* 52: 294.
- 759 57. Kamarudheen N, Rao KB (2019) Fatty acyl compounds from marine *Streptomyces*
760 *griseoincarnatus* strain HK12 against two major bio-film forming nosocomial
761 pathogens; an in vitro and in silico approach. *Microbial pathogenesis* 127: 121-130.
- 762 58. Li W-R, Xie X-B, Shi Q-S, Zeng H-Y, You-Sheng O-Y, et al. (2010) Antibacterial activity
763 and mechanism of silver nanoparticles on *Escherichia coli*. *Applied microbiology and*
764 *biotechnology* 85: 1115-1122.
- 765 59. Ivanova K, Fernandes MM, Mendoza E, Tzanov T (2015) Enzyme multilayer coatings
766 inhibit *Pseudomonas aeruginosa* biofilm formation on urinary catheters. *Applied*
767 *microbiology and biotechnology* 99: 4373-4385.
- 768 60. Saini H, Chhibber S, Harjai K (2016) Antimicrobial and antifouling efficacy of urinary
769 catheters impregnated with a combination of macrolide and fluoroquinolone antibiotics
770 against *Pseudomonas aeruginosa*. *Biofouling* 32: 511-522.
- 771 61. Francesko A, Fernandes MM, Ivanova K, Amorim S, Reis RL, et al. (2016) Bacteria-
772 responsive multilayer coatings comprising polycationic nanospheres for bacteria
773 biofilm prevention on urinary catheters. *Acta biomaterialia* 33: 203-212.

- 774 62. Rajkumar D, Rubini D, Sudharsan M, Suresh D, Nithyanand P (2020) Novel thiazolinyln-
775 picolinamide based palladium (II) complex-impregnated urinary catheters quench the
776 virulence and disintegrate the biofilms of uropathogens. *Biofouling* 36: 351-367.
- 777 63. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM (2000) A randomized
778 crossover study of silver-coated urinary catheters in hospitalized patients. *Archives of*
779 *Internal Medicine* 160: 3294-3298.
- 780 64. Yassin MA, Elkhoody TA, Elsherbiny SM, Reicha FM, Shokeir AA (2019) Facile coating
781 of urinary catheter with bio-inspired antibacterial coating. *Heliyon* 5: e02986.
- 782 65. Nicolle LE (2012) Urinary catheter-associated infections. *Infectious disease clinics of*
783 *North America* 26: 13-27.
- 784 66. Gurunathan S, Han JW, Kwon D-N, Kim J-H (2014) Enhanced antibacterial and anti-
785 biofilm activities of silver nanoparticles against Gram-negative and Gram-positive
786 bacteria. *Nanoscale research letters* 9: 1-17.
- 787 67. Dakal TC, Kumar A, Majumdar RS, Yadav V (2016) Mechanistic basis of antimicrobial
788 actions of silver nanoparticles. *Frontiers in microbiology* 7: 1831.
- 789 68. Maharjan G, Khadka P, Siddhi Shilpakar G, Chapagain G, Dhungana GR (2018) Catheter-
790 associated urinary tract infection and obstinate biofilm producers. *Canadian Journal of*
791 *Infectious Diseases and Medical Microbiology* 2018.
- 792 69. Manikandan M, Wu H-F (2013) Rapid differentiation and quantification of live/dead cancer
793 cells using differential photochemical behavior of acridine orange. *Photochemical &*
794 *Photobiological Sciences* 12: 1921-1926.
- 795 70. Slavin YN, Asnis J, Häfeli UO, Bach H (2017) Metal nanoparticles: understanding the
796 mechanisms behind antibacterial activity. *Journal of nanobiotechnology* 15: 1-20.

- 797 71. Tamayo L, Zapata P, Vejar N, Azócar M, Gulppi M, et al. (2014) Release of silver and
798 copper nanoparticles from polyethylene nanocomposites and their penetration into
799 *Listeria monocytogenes*. *Materials Science and Engineering: C* 40: 24-31.
- 800 72. Rothstein A (1971) Sulfhydryl groups in membrane structure and function. *Current topics*
801 *in membranes and transport*: Elsevier. pp. 135-176.
- 802 73. Lee SH, Jun B-H (2019) Silver nanoparticles: synthesis and application for nanomedicine.
803 *International journal of molecular sciences* 20: 865.
- 804 74. Sriram MI, Kalishwaralal K, Barathmanikanth S, Gurunathani S (2012) Size-based
805 cytotoxicity of silver nanoparticles in bovine retinal endothelial cells. *Nanoscience*
806 *Methods* 1: 56-77.
- 807 75. Abuayyash A, Ziegler N, Gessmann J, Sengstock C, Schildhauer TA, et al. (2018)
808 Antibacterial Efficacy of Sacrificial Anode Thin Films Combining Silver with Platinum
809 Group Elements within a Bacteria- Containing Human Plasma Clot. *Advanced*
810 *Engineering Materials* 20: 1700493.
- 811 76. Kim S-H, Lee H-S, Ryu D-S, Choi S-J, Lee D-S (2011) Antibacterial activity of silver-
812 nanoparticles against *Staphylococcus aureus* and *Escherichia coli*. *Microbiology and*
813 *Biotechnology Letters* 39: 77-85.
- 814 77. Chen D, Qiao X, Qiu X, Chen J (2009) Synthesis and electrical properties of uniform silver
815 nanoparticles for electronic applications. *Journal of materials science* 44: 1076-1081.
- 816 78. Khatoon Z, McTiernan CD, Suuronen EJ, Mah T-F, Alarcon EI (2018) Bacterial biofilm
817 formation on implantable devices and approaches to its treatment and prevention.
818 *Heliyon* 4: e01067.
- 819 79. Yun'an Qing LC, Li R, Liu G, Zhang Y, Tang X, et al. (2018) Potential antibacterial
820 mechanism of silver nanoparticles and the optimization of orthopedic implants by
821 advanced modification technologies. *International journal of nanomedicine* 13: 3311.

- 822 80. Farah MA, Ali MA, Chen S-M, Li Y, Al-Hemaid FM, et al. (2016) Silver nanoparticles
823 synthesized from *Adenium obesum* leaf extract induced DNA damage, apoptosis and
824 autophagy via generation of reactive oxygen species. *Colloids and Surfaces B:
825 Biointerfaces* 141: 158-169.
- 826 81. Gordon O, Vig Slenters Tn, Brunetto PS, Villaruz AE, Sturdevant DE, et al. (2010) Silver
827 coordination polymers for prevention of implant infection: thiol interaction, impact on
828 respiratory chain enzymes, and hydroxyl radical induction. *Antimicrobial agents and
829 chemotherapy* 54: 4208-4218.
- 830 82. Raja A, Ashokkumar S, Marthandam RP, Jayachandiran J, Khatiwada CP, et al. (2018)
831 Eco-friendly preparation of zinc oxide nanoparticles using *Tabernaemontana divaricata*
832 and its photocatalytic and antimicrobial activity. *Journal of Photochemistry and
833 Photobiology B: Biology* 181: 53-58.
- 834 83. Karygianni L, Ren Z, Koo H, Thurnheer T (2020) Biofilm matrixome: extracellular
835 components in structured microbial communities. *Trends in Microbiology* 28: 668-681.
- 836 84. Kassinger SJ, Van Hoek ML (2020) Biofilm architecture: An emerging synthetic biology
837 target. *Synthetic and systems biotechnology* 5: 1-10.
- 838 85. Carnerero JM, Jimenez- Ruiz A, Castillo PM, Prado- Gotor R (2017) Covalent and Non-
839 Covalent DNA–Gold- Nanoparticle Interactions: New Avenues of Research.
840 *ChemPhysChem* 18: 17-33.
- 841 86. Koo KM, Sina AA, Carrascosa LG, Shiddiky MJ, Trau M (2015) DNA–bare gold affinity
842 interactions: mechanism and applications in biosensing. *Analytical Methods* 7: 7042-
843 7054.
- 844 87. Jiang W-Y, Ran S-Y (2018) Two-stage DNA compaction induced by silver ions suggests
845 a cooperative binding mechanism. *The Journal of chemical physics* 148: 205102.

- 846 88. Tian H, Liao Q, Liu M, Hou J, Zhang Y, et al. (2015) Antibacterial activity of silver
847 nanoparticles target sara through srna-teg49, a key mediator of hfq, in staphylococcus
848 aureus. *International journal of clinical and experimental medicine* 8: 5794.
- 849 89. Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, et al. (2012) The molecular mechanism of action
850 of bactericidal gold nanoparticles on *Escherichia coli*. *Biomaterials* 33: 2327-2333.
- 851 90. Mohanta YK, Biswas K, Jena SK, Hashem A, Abd_Allah EF, et al. (2020) Anti-biofilm
852 and antibacterial activities of silver nanoparticles synthesized by the reducing activity
853 of phytoconstituents present in the Indian medicinal plants. *Frontiers in Microbiology*
854 11.
- 855 91. Rodríguez-Serrano C, Guzmán-Moreno J, Ángeles-Chávez C, Rodríguez-González V,
856 Ortega-Sigala JJ, et al. (2020) Biosynthesis of silver nanoparticles by *Fusarium scirpi*
857 and its potential as antimicrobial agent against uropathogenic *Escherichia coli* biofilms.
858 *Plos one* 15: e0230275.
- 859 92. Joshi AS, Singh P, Mijakovic I (2020) Interactions of gold and silver nanoparticles with
860 bacterial biofilms: Molecular interactions behind inhibition and resistance.
861 *International Journal of Molecular Sciences* 21: 7658.
- 862 93. Kalishwaralal K, BarathManiKanth S, Pandian SRK, Deepak V, Gurunathan S (2010)
863 Silver nanoparticles impede the biofilm formation by *Pseudomonas aeruginosa* and
864 *Staphylococcus epidermidis*. *Colloids and Surfaces B: Biointerfaces* 79: 340-344.
- 865 94. Singh R, Hano C, Nath G, Sharma B (2021) Green Biosynthesis of Silver Nanoparticles
866 Using Leaf Extract of *Carissa carandas* L. and Their Antioxidant and Antimicrobial
867 Activity against Human Pathogenic Bacteria. *Biomolecules* 11: 299.
- 868 95. John A, Shaji A, Vealyudhannair K, Nidhin M, Krishnamoorthy G (2021) Anti-bacterial
869 and biocompatibility properties of green synthesized silver nanoparticles using *Parkia*

870 biglandulosa (Fabales: Fabaceae) leaf extract. Current Research in Green and
871 Sustainable Chemistry: 100112.

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895 **Table 1** Antibacterial activity against Uropathogens

896	Bacteria	ZoI of <i>C. carandas</i> (mm)				
		25µg/ml	50µg/ml	75 µg/ml	100µg/ml	125 µg/ml
898	<i>S. aureus</i>	8±0.3	10 ±0.3	13 ±0.3	15 ±0.3	17 ±0.1
899	<i>E. coli</i>	10 ±0.1	13 ±0.2	13 ±0.2	13 ±0.3	15 ±0.2
900	<i>P. aeruginosa</i>	8 ±0.2	9 ±0.2	10 ±0.5	13 ±0.2	15 ±0.1

905 **Table 2** Comparative analysis against Uropathogens (ZOI)

Strains	ZoI of <i>C. carandas</i> (mm)					
	Crude extract	AgNo3	AgNPs	Ciprofloxacin	Uncoated catheter	AgNPs Coated Catheter
<i>S. aureus</i>	-	11 ±0.3	17±0.2	16±0.3	No zone	17±0.4
<i>E. coli</i>	-	13±0.1	21±0.3	17±0.2	No zone	21±0.3
<i>P. aeruginosa</i>	-	10±0.4	13±0.3	10±0.1	No zone	13±0.1

906

907

908

909

910

911

912

913

914

915 **Table 3** Zone of Inhibition of different antibiotics against uropathogens with presence and
 916 absence of AgNPs.

917

Strains	Antibiotics	ZoI (mm)		
		Antibiotics (a)	Antibiotic + AgNPs (b)	Increase in fold area ($b^2 - a^2/a^2$)
<i>S. aureus</i>	Ciprofloxacin	16	19	0.41
	Gentamycin	27	29	0.15
	Trimethoprim	No zone	11	2.3
<i>E. coli</i>	Ciprofloxacin	22	24	0.19
	Gentamycin	19	20	0.10
	Trimethoprim	7	10	1.04
<i>P. aeruginosa</i>	Ciprofloxacin	23	25	0.18
	Gentamycin	16	19	0.41
	Trimethoprim	5	11	3.84

918

919

920

921

922

923

924

925

926

927

928 **Figure legends**

929 **Fig 1.** UV-visible spectra of *Carissa carandas* leaf mediated synthesized AgNPs (before
930 optimization procedure), AgNO₃, *Carissa carandas* leaf extract.

931 **Fig 2.** UV – vis spectra of aqueous AgNO₃ with *Carissa carandas* leaf extract at (A)different
932 pH (B) different substrate concentration (C) different silver ion concentration (D) different time
933 intervals.

934 **Fig 3.** Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using
935 (A)EDX (B) XRD.

936 **Fig 4.** Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using
937 (A)TEM (B) Histogram (C) SAED (D) FTIR

938 **Fig 5.** Antibacterial activity of different concentrations of *C. carandas* mediated synthesized
939 AgNPs against the test pathogens. (1) Zone of Inhibition in different concentrations
940 (A-25µg/mL, B-50 µg/mL, C-75 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against
941 *Escherichia coli* AMB4. (2) Zone of Inhibition in different concentrations (A-25µg/mL, B-50
942 µg/mL, C-75 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against *Staphylococcus aureus*
943 AMB6. (3) Zone of Inhibition in different concentrations (A-25µg/mL, B-50 µg/mL, C-75
944 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against *Pseudomonas aeruginosa* AMB5

945 **Fig 6.** Antibacterial comparison of *C. carandas* mediated synthesized AgNPs, commercial
946 antibiotics (ciprofloxacin), *C. carandas* leaf extract, AgNO₃ against test pathogens.
947 (1) Zone of inhibition observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and
948 commercial antibiotic (ciprofloxacin) against *Escherichia coli* AMB4. (2) Zone of inhibition
949 observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic
950 (ciprofloxacin) against *Staphylococcus aureus* AMB6. (3) Zone of inhibition observed in the

951 well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic (ciprofloxacin)
952 against *Pseudomonas aeruginosa* AMB5.

953 **Fig 7.** Minimum inhibitory concentration for different concentrations (20, 40, 60, 80, 100, 120,
954 140, and 160µg/ml) of AgNPs against *Escherichia coli* AMB4, *Pseudomonas aeruginosa*
955 AMB5, *Staphylococcus aureus* AMB6.

956 **Fig 8.** Urinary catheter coated with AgNPs and uncoated catheter (A) *C. carandas* leaf
957 mediated synthesized AgNPs coated urinary catheter of size 1× 1 cm (B) uncoated urinary
958 catheter of size 1×1 cm

959 **Fig 9.** Biofilm inhibition percentage of AgNPs coated catheter. AgNPs coated catheter with
960 different concentration of 20,40,80,120,160 µg/mL shows biofilm inhibition towards
961 *Escherichia coli* AMB4, *Pseudomonas aeruginosa* AMB5, *Staphylococcus aureus* AMB6.

962 **Fig 10.** SEM analysis of urinary catheter (A) SEM micrograph of uncoated urinary catheter
963 (control) (B) SEM micrograph of urinary catheter coated with 30 µg/mL of AgNPs, arrow
964 indicate the coating of AgNPs (C) SEM micrograph of biofilm mat formed by *Escherichia coli*
965 AMB4 over uncoated urinary catheter, arrow indicates the mat formation (D) SEM micrograph
966 showing the disruption of biofilm formed by *Escherichia coli* AMB4 over AgNPs coated
967 urinary catheter, arrow indicates the disruption of biofilm.

968 **Fig 11.** Proposed antibacterial mechanism of plant mediated AgNPs showing various
969 inhibiting properties of AgNPs. 1) AgNPs interact with ribosome and inhibit the translation; 2)
970 AgNPs have electrostatic interaction with the cell wall which ultimately causes the leakage of
971 internal substances; 3) AgNPs interact with sulfhydryl group of enzymes and proteins, hence
972 protein denaturation takes place; 4) AgNPs inactivates the respiratory chain and excess ROS
973 generation, results in the apoptosis; 5) AgNPs anchor the cell wall of the bacteria and causes
974 damages to the cell membrane and the cellular content get leaked.

975 **Fig 12.** Proposed antibiofilm mechanism of plant mediated AgNPs. (1) AgNPs has
976 electrostatic interaction with the cells and disturb the biofilm formation; (2) AgNPs penetrate
977 the biofilm and creates anti-adherence which ultimately cause the leakage of cellular contents;
978 (3) AgNPs degrade the EPS formation and breaks the biofilm mat; (4) AgNPs inhibits the signal
979 produced by the bacteria, thereby inhibiting the biofilm formation.

980

981




Fig 1. UV-visible spectra of *Carissa carandas* leaf mediated synthesized AgNPs (before optimization procedure), AgNO₃, *Carissa carandas* leaf extract.




Fig 2. UV – vis spectra of aqueous AgNO_3 with *Carissa carandas* leaf extract at (A) different pH (B) different substrate concentration (C) different silver ion concentration (D) different time intervals.





Fig 3. Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using (A)EDX (B) XRD.




Fig 4. Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using (A)TEM (B) Histogram (C) SAED (D) FTIR




Fig 5. Antibacterial activity of different concentrations of *C. carandas* mediated synthesized AgNPs against the test pathogens. (1) Zone of Inhibition in different concentrations (A-25 μ g/mL, B-50 μ g/mL, C-75 μ g/mL, D-100 μ g/mL, E-125 μ g/mL) of AgNPs against *Escherichia coli* AMB4. (2) Zone of Inhibition in different concentrations (A-25 μ g/mL, B-50 μ g/mL, C-75 μ g/mL, D-100 μ g/mL, E-125 μ g/mL) of AgNPs against *Staphylococcus aureus* AMB6. (3) Zone of Inhibition in different concentrations (A-25 μ g/mL, B-50 μ g/mL, C-75 μ g/mL, D-100 μ g/mL, E-125 μ g/mL) of AgNPs against *Pseudomonas aeruginosa* AMB5




Fig 6. Antibacterial comparison of *C. carandas* mediated synthesized AgNPs, commercial antibiotics (ciprofloxacin), *C. carandas* leaf extract, AgNO₃ against test pathogens. (1) Zone of inhibition observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic (ciprofloxacin) against *Escherichia coli* AMB4. (2) Zone of inhibition observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic (ciprofloxacin) against *Staphylococcus aureus* AMB6. (3) Zone of inhibition observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic (ciprofloxacin) against *Pseudomonas aeruginosa* AMB5




Fig 7. Minimum inhibitory concentration for different concentrations (20, 40, 60, 80, 100, 120, 140, and 160µg/ml) of AgNPs against *Escherichia coli* AMB4, *Pseudomonas aeruginosa* AMB5, *Staphylococcus aureus* AMB6.




Fig 8. Urinary catheter coated with AgNPs and uncoated catheter (A) *C. carandas* leaf mediated synthesized AgNPs coated urinary catheter of size 1×1 cm (B) uncoated urinary catheter of size 1×1 cm




Fig 9. Biofilm inhibition percentage of AgNPs coated catheter. AgNPs coated catheter with different concentration of 20,40,80,120,160 µg/mL shows biofilm inhibition towards *Escherichia coli* AMB4, *Pseudomonas aeruginosa* AMB5, *Staphylococcus aureus* AMB6.





Fig 10. SEM analysis of urinary catheter (A) SEM micrograph of uncoated urinary catheter (control) (B) SEM micrograph of urinary catheter coated with 30 μg/mL of AgNPs, arrow indicate the coating of AgNPs (C) SEM micrograph of biofilm mat formed by *Escherichia coli* AMB4 over uncoated urinary catheter, arrow indicates the mat formation (D) SEM micrograph showing the disruption of biofilm formed by *Escherichia coli* AMB4 over AgNPs coated urinary catheter, arrow indicates the disruption of biofilm.



11. Proposed antibacterial mechanism of plant mediated AgNPs showing various inhibiting properties of AgNPs. 1) AgNPs interact with ribosome and inhibit the translation; 2) AgNPs have electrostatic interaction with the cell wall which ultimately causes the leakage of internal substances; 3) AgNPs interact with sulfhydryl group of enzymes and proteins, hence protein denaturation takes place; 4) AgNPs inactivates the respiratory chain and excess ROS generation, results in the apoptosis; 5) AgNPs anchor the cell wall of the bacteria and causes damages to the cell membrane and the cellular content get leaked.







Fig 12. Proposed antibiofilm mechanism of plant mediated AgNPs. (1) AgNPs has electrostatic interaction with the cells and disturb the biofilm formation; (2) AgNPs penetrate the biofilm and creates anti-adherence which ultimately cause the leakage of cellular contents; (3) AgNPs degrade the EPS formation and breaks the biofilm mat; (4) AgNPs inhibits the signal produced by the bacteria, thereby inhibiting the biofilm formation.




Click here to access/download
Supporting Information
Graphical Abstract.docx





Click here to access/download
Supporting Information
Minimal Data.docx



1 **Bioengineered phytomolecules-capped silver nanoparticles**
2 **using *Carissa carandas* leaf extract to embed on to urinary**
3 **catheter to combat UTI pathogens**

4 Haajira Beevi Habeeb Rahuman^{1¶}, Ranjithkumar Dhandapani^{1¶}, Velmurugan Palanivel^{2*},
5 Sathiamoorthi Thangavelu¹, Ragul Paramasivam³, Muthupandian Saravanan^{4,5*}

6 ¹ Department of Microbiology, Science Campus, Alagappa University, Karaikudi- 630 003,
7 Tamilnadu, India

8 ² Centre for for Material Engineering and Regenerative Medicine Bharath Institute of Higher
9 Education, Chennai, India.

10 ³ Chimertech Innovations LLP, Tamilnadu Veterinary and Animal Science University,
11 Chennai, India

12 ⁴ Division of Biomedical sciences, College of Health Sciences, School of Medicine, Mekelle,
13 Ethiopia.

14 ⁵ AMR and Nanomedicine Laboratory, Department of Pharmacology, Saveetha Dental
15 College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai 600 077,
16 Chennai, India

17 [¶]These authors have contributed equally to this work

18

19 ***Corresponding authors:** Muthupandian Saravanan, Email: bioinfosaran@gmail.com,

20 Velmurugan Palanivel, Email: palanivelmurgan2008@gmail.com.

21

22

23

24 **Abstract**

25 Rising incidents of urinary tract infections (UTIs) among catheterized patients is a
26 noteworthy problem in clinic due to their colonization of uropathogens on abiotic surfaces.
27 Herein, we have examined the surface modification of urinary catheter by embedding with eco-
28 friendly **synthesized phytomolecules-capped silver nanoparticles** (AgNPs) to prevent the
29 invasion and colonization of uropathogens. The preliminary confirmation of AgNPs production
30 in the reaction mixture was witnessed by the colour change and surface resonance plasmon
31 (SRP) band at 410nm by UV–visible spectroscopy. The morphology, size, crystalline nature,
32 and elemental composition of attained AgNPs were further confirmed by the transmission
33 electron microscopy (TEM), selected area electron diffraction (SAED), X-ray diffraction
34 (XRD) technique, Scanning electron microscopy (SEM) and energy dispersive spectroscopy
35 (EDS). The functional groups of AgNPs with stabilization/capped phytochemicals were
36 detected by Fourier-transform infrared spectroscopy (FTIR). Further, antibiofilm activity of
37 synthesized AgNPs against biofilm producers **such as** *Staphylococcus aureus*, *Escherichia coli*
38 and *Pseudomonas aeruginosa* **were determined by viability assays and micrographically.**
39 AgNPs coated and coating-free catheters performed to treat with bacterial pathogen to analyze
40 the mat formation and disruption of biofilm formation. Synergistic effect of AgNPs with
41 antibiotic reveals that it can enhance the activity of antibiotics, AgNPs coated catheter **revealed**
42 **that, it has** potential antimicrobial activity and antibiofilm activity. In summary, *C. carandas*
43 leaf extract mediated synthesized AgNPs will open a new avenue and a promising template to
44 embed on urinary catheter to control clinical pathogens.

45 **Key words:** AgNPs, Uropathogens, Urethral catheter, Surface modification,
46 Biocompatibility, Synergistic effect.

47

48 Introduction

49 UTI is broadly defined as a symptomatic or asymptomatic infection in both upper and
50 lower urinary system which involves initial adhesion and colonization on the surface of the
51 medical devices (catheter). The bacteria implicated in UTIs are *Staphylococcus sp.*,
52 *Streptococcus sp.*, *Klebsiella sp.*, *Enterococcus sp.*, *Proteus sp.*, *Pseudomonas sp.*, and
53 *Escherichia coli* owing to its biofilm assembly capacity [1-3]. Among most of the UTI cases,
54 80% are allied with ingrained urinary catheters [4] and associated UTIs are foremost common
55 infection throughout the world [5]. The colonization of microbial community on medical
56 devices forms a polymicrobial aggregates called “biofilm”. Self-generated extracellular
57 polymeric matter adheres the surface of the hospital acquired devices give rise to implant
58 failure. It has been accounted that to control biofilm forming bacteria needs 1500 times higher
59 concentration of antibiotics when compared to planktonic bacteria [6]. The existence of urine
60 in urinary catheters makes an appropriate habitation for urease-positive microbes. The pH of
61 the urine increases due to the presence of ammonia which makes the deposition of calcium and
62 magnesium phosphate on catheter can ultimately leads to thorough constriction of the biofilm
63 on catheter over coating or crystalline biofilms [7]. The UTI bacteria cause serious concerns
64 due to spreading to kidney and cause acute or chronic pyelonephritis [8]. Increased antibiotic
65 resistance of biofilm was formed by extracellular polymeric substances (EPS) matrix, found in
66 the biofilm communities which makes the treatment ineffective [9]. A review by [8] Singha et
67 al., 2017 described the several attempts have been made to impregnating antimicrobial coating
68 on catheter with antibiotics, antimicrobial agents (both biocidal and antifouling), antimicrobial
69 peptides, bacteriophages, enzymes, nitric oxide, polyzwitterions, polymeric coating
70 modifications, liposomes. These coating have shown good antimicrobial activity *in vitro*,
71 however a few drawbacks are shortlisted including resistance development. Silver
72 nanoparticles produced from the phytochemicals of *C. carandas* leaf extract have been studied

73 as a major and promising antibacterial alternative and also inhibit the biofilm formation in UTI
74 pathogens. It was coated as an antimicrobial nanomaterial in the urinary catheter to prevent
75 catheter associated UTI infection.

76 Among the various inorganic metal nanoparticles, silver nanoparticles (AgNPs) have
77 gained its attention for various reasons such as low toxicity, environment friendly and also
78 known for its antibacterial activity against the bacteria exhibiting resistance to antibiotics [10].
79 Silver exhibits excellent antimicrobial activity and the production of nanomaterial through
80 physical and chemical approaches will have an adverse effect in environment due to the
81 adsorption of toxic substance as a reducing agent [11]. The system of phytochemical mediated
82 synthesis of nanomaterial is a promising eco-friendly, non-toxic, cheap substrate, easily
83 available, convenient and quickly processable to fabricate antimicrobial nanomaterial[11,12].
84 *C. carandas* belongs to the species of flowering shrub in dogbane family, Apocyanaceae.
85 *Carissa carandas* spread widely throughout the tropical and subtropical region of India. The
86 plant possessing phytochemical constituents has high medicinal values [13]. In traditional
87 medicine, *Carissa carandas* leaf, bark, fruit, root have been used to treat several human
88 ailments such as hepatomegaly, indigestion, amenorrhea, oedema, colic, piles, antipyretic,
89 fever, liver dysfunction, stomach pain, skin infections, intestinal worms, antimicrobial,
90 antifungal [14-16]. The leaf of *C. carandas* has anticancer, antimicrobial, antioxidant property
91 and non-mutagenic property [17]. The leaf decoction is used to treat against sporadic fever,
92 remedy for diarrhea, earache, syphilitic pain, oral inflammation and snake bite poisoning [18].
93 Since this plant has many medicinal values and very less literature availability for *C. carandas*
94 leaf extract.

95 In this research, the leaf extract of *C. carandas* was used to reduce the precursor
96 solution of silver nitrate to AgNPs and this production was optimized by modifying parameters
97 of synthesis such as pH, *C. carandas* leaf extract, metal ion concentration, and production time.

98 Characterization of synthesized AgNPs was done by UV Vis spectrophotometry, TEM, XRD,
99 EDS, FTIR and SAED pattern. The synthesized AgNPs was investigated for antimicrobial
100 activity and embedded on catheter to investigate the property as antimicrobial nanomaterial to
101 inhibit catheter associate UTI infection.

102 **Materials and Method**

103 **Chemicals and biological materials**

104 Fresh leaves of *C. carandas* were collected from Periyakulam, Theni District,
105 Tamilnadu, India (10.1239° N, 77.5475° E) and washed thoroughly to remove the dust. Silver
106 nitrate (AgNO_3), Muller Hinton Agar (MHA), Lysogenic broth (LB), trypticase soya broth
107 (TS) was acquired from Hi-media and used to assess antibacterial, antibiofilm assays. Bacterial
108 pathogens such as *Escherichia coli* AMB4 (MK788230), *Pseudomonas aeruginosa* AMB5
109 (clinical sample), *Staphylococcus aureus* AMB6 (Clinical sample) was maintained by
110 Department of Microbiology, Alagappa University, Science campus, Karaikudi, India.

111 **Extract preparation**

112 Cleaned *C. carandas* leaves were subjected to air dry and quantified the weight of 100
113 grams. Dried leaves were soaked in 300 mL of Millipore water and allowed to boil for 1 h at
114 80°C to avail decoction of leaf extract which was percolated through Whatmann no.1 filter
115 paper and stored at 4 °C for future use.

116 **Synthesis and optimization of AgNPs production**

117 The AgNPs synthesis was carried out by adding 1mL of filtered *C. carandas* leaf extracts
118 and 9mL of 1.25mM aqueous silver nitrate solution (AgNO_3) in the ratio of 1:9 was incubated at
119 ambient temperature under dark condition. Initial AgNPs production was confirmed by visual color
120 change from light yellow to dark brown color and scanning the absorbance along the UV-Vis range
121 (200-600 nm) of the electromagnetic spectra using an UV-Visible Spectrophotometer (Shimadzu

122 UV 1800, Japan). To achieve large scale production of AgNPs, optimization procedure was
123 followed by modifying the parameters like pH, substrate (extract), metal ion concentration and
124 production time. Briefly, pH of the solution was optimized by modifying the solution to various
125 pH 2, 3, 4, 5, 6, 7, 8, 9, 10 with 1mL substrate (extract) concentration and 0.1mM metal ion
126 concentration, left overnight under dark condition. Substrate concentration was optimized by
127 modifying the solution to various concentration like 0.1, 0.5, 0.75, 1, 1.25, 1.5, 1.75 mL with the
128 optimized pH as a standard and 0.1mM metal ion concentration, left overnight under dark
129 condition. Ag⁺ ion concentration was optimized by modifying the solution to various metal ion
130 concentration such as 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5mM with the optimized pH and
131 optimized substrate concentration, left overnight under dark condition. Then finally production
132 time was optimized by measuring the absorbance at various time intervals such as 0, 5, 10, 15, 20,
133 25, 30 mins with the optimized pH, substrate and metal ion concentration using UV-Visible
134 Spectrophotometer. With the optimized parameters the optimum production was set for the large-
135 scale production. The heterogeneous mixture was centrifuged at 12000 rpm for 20 min followed
136 by collection of pellets; washed with methanol: water ratio at 6:4 and lyophilized to obtain
137 nanoparticles powder.

138 **Characterization of nanoparticles**

139 XRD (X-ray diffraction) analysis of silver nanoparticles was recorded by P analytical
140 X' Pert PRO powder which was operated at a voltage of 40kV with the current of 30 mA using
141 Cu-K α radiation of wavelength 1.5406 Å in the 2 θ range of 20° - 80° to obtain the crystalline
142 structure of the AgNPs. Involvement of functional group in synthesis of nanoparticles and
143 capping material was monitored by FTIR (Fourier Transform Infrared spectrophotometer) and
144 performed to analyze the presence of functional groups of AgNPs and capping phytochemicals
145 using attenuated total reflectance (ATR) mode (Nicolet iS5, Thermo Fisher Scientific Inc.,
146 Marietta, GA, USA). EDX (Energy dispersive X-ray) analysis was performed to determinate

147 the elemental composition (Tescan VEGA 3SBH with Brukar easy). HR-TEM (High resolution
148 Transmission Electron microscope) (JEOL-2100+, Japan) and SAED (selected area Electron
149 Diffraction) pattern were analyzed to examine the size, crystalline structure and surface
150 morphology of AgNPs.

151 **Antibacterial activity**

152 Each test bacterial strain of 0.5 McFarland standards [19] was swabbed on MHA plates
153 using a sterile swab and a well of 8mm width was formed using a sterile well borer under
154 aseptic condition. Different concentrations of AgNPs 25, 50, 75, 100, 125µg/mL (1mg/mL
155 stock solution was prepared for synthesized AgNPs, from the stock solution 25 µl was
156 dissolved in 975 µl of DMSO to make 25µg/mL concentration and further concentrations were
157 prepared accordingly) were loaded in the MHA plates along with the DMSO as solvent control
158 and incubated at 37°C for 24 h. After incubation, zone of inhibition (ZoI) was measured to the
159 nearest millimeter from end of the well to end of the zone.

160 Comparison was made with AgNPs (125 µg / mL), crude leaf extract (50µg/mL),
161 1.25mM AgNO₃ solution, 99.8% of DMSO as a solvent negative control and ciprofloxacin
162 (50µg/ml) as positive control for assessment were loaded consequently in the agar wells made
163 in MHA plate and incubated at 37°C for 24 h. After incubation, zone of inhibition (ZoI) was
164 measured to the nearest millimeter from end of the well to end of the zone.

165 **Minimum Inhibitory (MIC) and Minimum Bactericidal**

166 **Concentration (MBC)**

167 The MIC and MBC was performed to evaluate the efficiency of obtained AgNPs
168 to inhibit bacterial pathogens and protocol was followed according to the guidance of CLSI.
169 MIC was performed by 96 microtiter well plate by broth micro dilution method. 10⁶CFU/mL
170 concentration of bacterial inoculum (10µl) was inoculated with different concentrations of

171 AgNPs (20, 40, 60, 80, 100, 120, 140, and 160µg/ml) and incubated at 37 °C for 24 h. After
172 incubation well plates were recorded by ELISA reader at 590nm to assess its optical density
173 value. MIC was analyzed to determine the efficacy of appropriate concentration of AgNPs
174 required inhibiting the bacterial growth. The inhibition rate can be estimated as follows

$$175 \quad \% \text{ Inhibition rate} = 100 \times \frac{(OD_{\text{untreated}} - OD_{\text{well}})}{(OD_{\text{untreated}} - OD_{\text{blank}})} \quad (1)$$

176 Where $OD_{\text{untreated}}$ = optical density of bacterial cell without AgNPs, OD_{well} = optical density of
177 bacterial cell with AgNPs, OD_{blank} = sterile culture medium.

178 The MIC endpoint is the lowest concentration of silver nanoparticles where no visible growth
179 is seen in the well. The visual turbidity was noted, both before and after incubation of well
180 plate to confirm MIC value [20].

181 After incubation the titer plates were agitated gently for 10 min and the broth in the
182 well were plated on MHA plate and incubated during 24h, the CFU was counted and bacterial
183 viability was calculated in order to calculate the MBC. MBC cutoff occurs when 99.9% of the
184 microbial population is destroyed at the lowest concentration of AgNPs [20].

185 **Synergistic effect of silver nanoparticles with commercial** 186 **antibiotics**

187 Synergistic effect of silver nanoparticles with commercial antibiotics for uropathogens
188 was done by disk diffusion method. Commercial antibiotic discs were impregnated with
189 synthesized AgNPs (Ciprofloxacin -50mcg, Trimethoprim – 30 mcg, Gentamycin – 30 mcg)
190 in the concentration of 20µg/mL and allowed to air dry. Then MHA plates were prepared and
191 inoculated with overnight bacterial culture in the turbidity of 0.5% of McFarland standard.
192 Commercial antibiotic disc impregnated with AgNPs was placed on the MHA plates and
193 control plates were swabbed with test culture and placed with commercial discs aseptically.
194 These plates were incubated at 37 °C for 24 h and the zone of inhibition was measured[21].

195 **Qualitative assay for biofilm formation**

196 Qualitative assessment of the pathogen's biofilm potential was performed by test tube
197 method according to [7] Doll et al., 2016. Briefly, trypticase soy broth was inoculated with
198 loop full of mid-log phase pathogen and incubated at 37 °C for 24 h. Uninoculated broth was
199 considered as a control. The broth was removed 24 hours of incubation and tubes were cleaned
200 with sterile Phosphate buffered saline PBS with the pH of 7.4. The tubes were dried and stained
201 for 10 minutes with 0.1 percent crystal violet. Extra dye was removed with sterile distilled
202 water and stained film formed at the tube's base, indicating the development of biofilm [22].

203 **Quantitative assay for biofilm formation**

204 Development of static biofilm formation was confirmed by quantitative assay by
205 microtiter plate method. Mid-log phase culture was diluted ten times using a sterile media. The
206 culture was transferred to microtiter plate. The plates were incubated at 37 °C for 16h. After
207 incubation, planktonic cells were removed using PBS (pH 7.2) and dried, subsequently the
208 plates were stained with 125µL of 0.1 % CV solution. Dye in the well surface was solubilized
209 using 200µL of 30% glacial acetic acid, the content of each well was mixed and transferred to
210 sterile well plate and this setup was read at 590nm. The test organisms were classified as
211 weakly, moderately adherent, non-adherent and strongly adherent bacteria based on the criteria
212 ($OD < OD_c$ = Non adherent, $OD_c < OD < 2 \times OD_c$ = weakly adherent, $2 \times OD_c < OD < 4 \times OD_c$ =
213 moderately adherent, $4 \times OD_c < OD$ = strongly adherent where OD_c = average OD of negative
214 control [23].

215 **Coating of urinary catheter with AgNPs**

216 Urinary Catheter was segmented to 1×1cm. Catheter pieces were entirely dipped in
217 synthesized AgNPs suspension with different concentration of AgNPs coated catheter such as

218 20µg/mL, 40µg/mL, 80µg/mL, 120µg/mL, 160µg/mL for 24 h. Excess of suspension was
219 removed by blotting and dried at 50°C [24].

220 **Biofilm inhibition in AgNPs coated catheter**

221 Conical flask containing 25mL of sterile trypticase soy broth inoculated with 100 µL
222 of mid-log phase pathogenic culture. Two sterile catheters were introduced into the medium
223 using sterile forceps. Different concentration of synthesized AgNPs coated catheter (20µg/mL,
224 40µg/mL, 80µg/mL, 120µg/mL, 160µg/mL) was introduced into the medium using sterile
225 forceps. Later, this setup was subjected to incubation for 24h at 37 °C. Sterile broth was
226 maintained as negative control. Biofilm control was maintained with pathogen in the growth
227 medium. After incubation, the catheters were removed from broth and transferred into sterile
228 PBS phosphate buffered saline to get rid of planktonic cells and then the catheter was stained
229 with 0.1% crystal violet (CV) for 10 mins. The catheters were dried and observed under
230 compound microscope.

231 Staining solutions were made out by mixing 0.05mL of stock solution of 1% Acridine
232 orange with 5mL of acetate buffer 0.2M (pH4). Sterile catheter was placed with AgNPs treated
233 and untreated bacterial pathogen and allowed to dried at 50°C, the bacterial cells adhered to
234 catheter surface was fixed with absolute methanol and stained with Acridine orange for 1 min,
235 rinsed with distilled water and dried. The catheters were observed for fluorescence microscope
236 [25]. The biofilm can be observed on the surface of the catheter [26].

237 Biofilm inhibition percentage of the urinary catheter coated with AgNPs was studied
238 using microtiter well plate method. 50µL of TSB diluted with 10µL of mid-log phase culture
239 was added to the wells. Different concentration of AgNPs coated catheter
240 (20µg/mL,40µg/mL,80 µg/mL,120µg/mL,160µg/mL) was added to the respective wells. Test
241 culture with uncoated sterile catheter act as a negative control. The well plates were incubated
242 for 24h at 37 °C [3]. After 24 h incubation, the catheters were removed and washed twice with

243 sterile distilled water to remove the planktonic cells. Catheter containing biofilm was stained
244 with 1mL of 0.4% CV solution and then washed with sterile distilled water to remove excess
245 stain. Stain was then solubilized by 1mL of absolute ethanol. The well plates were read for OD
246 value at 590nm using micro titer plate reader. Conducted experiments were done in triplicate
247 and graph was drawn using graph pad prism version 9.1.2.

248 The inhibition percentage was calculated by the formula

$$249 \frac{(Ab_c - Ab_t)}{Ab_c} \times 100 \quad (2)$$

250 Where Ab_c = absorbance of control well Ab_t = absorbance of test well

251 **Antibacterial activity of AgNPs coated urinary catheter**

252 Antibacterial activity of AgNPs coated catheter was assessed by the following
253 procedure. Each test bacterial strain of 0.5 McFarland standards [19,27] was swabbed on MHA
254 plates using a sterile swab. AgNPs coated catheter and uncoated catheter was situated on agar
255 and incubated at 37 °C for 24 h and zone of inhibition was observed and measured [27].

256 **SEM analysis of urinary catheter**

257 AgNPs coated catheter and uncoated catheter pieces were introduced into trypticase soy
258 broth which is inoculated with a strong biofilm former *E. coli* AMB4, aseptically for 48 h at
259 37 °C. To analyze SEM, catheters were fixed with 2.5% of Glutaraldehyde in 0.1M sodium
260 phosphate buffer for 3 hours and washed with 0.1M sodium phosphate buffer. Then the sample
261 was allowed to dehydrate through a series of ethanol wash: 30%, 50%, 80% for 10 min [21,28].

262 **Result**

263 **Optimization of AgNPs production**

264 Initially the preliminary confirmation of AgNPs production in the reaction mixture
265 through green process was observed through the visual color change followed by surface

266 plasmon resonance (SPR) using UV–visible spectroscopy as a tremendous tool. An intense
267 peak at 410nm by UV–visible absorption spectra confirmed the formation of colloidal AgNPs.
268 *Carissa carandas* leaf extract pH was found to be pH 7 and the UV spectra of the leaf extract
269 was observed as shown in the Fig 1. There is no interesting λ_{\max} peak in *C. carandas* leaf extract
270 and silver nitrate solution as shown in the Fig 1. Optimum reduction of Ag^+ by *C. carandas*
271 leaf extract to attain the maximum AgNPs production was succeeded by modifying the pH,
272 substrate concentration, silver ion concentration, and production time and their wavelength
273 were revealed in Figs 2 (A, B, C and D). In summary, pH is one of the most important variables
274 in nanoparticle products. In acidic environment, particles did not form (pH 2 and 3). At alkaline
275 pH 10, the color production occurred quick, although only weak peak was visible. The reaction
276 was begun as soon as the silver nitrate was introduced to the reaction at neutral pH 7. The
277 solution changed color from pale yellowish to dark brown, indicating the production of silver
278 nanoparticles. Production of AgNPs was further verified by the characteristic absorption peak
279 (Fig 2 A) at 410nm in the UV-visible spectrum. Interestingly a strong intense peak was
280 observed at pH 9 at the same wavelength of 410nm but the agglomeration of the reaction was
281 observed.

282 Different concentration of *C. carandas* leaf extract was optimized for maximum
283 production of AgNPs. However, the different extract concentration shows peak at 410nm.
284 Interestingly 10ml of reaction mixture containing 1.25mL of leaf extract (Fig 2 B) was turned
285 to dark brown immediately after the addition to 0.1mM of silver nitrate solution at an optimized
286 pH 7.

287 Different concentration of silver nitrate was optimized for the maximum synthesis of
288 AgNPs. 1.25mM concentration of silver nitrate (Fig 2C) shows a strong intense peak at 410nm
289 and the reaction mixture was turned immediately to dark brown after the addition optimized

290 leaf extract of 1.25mL and altering to optimized pH 7. However, 2.0mM, 1.75mM and 1.5mM
291 silver nitrate concentration shows much weaker absorbance peak at 410nm.

292 Time taken for the maximum AgNPs production was optimized by measuring the
293 reaction solution in UV-visible spectroscopy at a various time interval, where the reaction
294 mixture contains optimized silver nitrate concentration of 1.25mM with optimized substrate
295 concentration of 1.25ml at an optimized pH 7. And the dark brown color occurred within
296 20min of incubation, suggesting that AgNPs formed quickly. However, the color change
297 observed in 25 and 30 mins was very dark than the color obtained in 20mins (Fig 2D), the
298 absorbance spectra at 25 and 30 mins showed weak characteristic peak. As a result, the
299 optimized medium enabled for the greatest production of silver nanoparticles, and the reaction
300 took place quickly.

301 **Characterization of nanoparticles**

302 **EDS**

303 Presence of silver element in synthesized AgNPs was confirmed by Energy Dispersive
304 analysis Fig 3 (A). Metallic AgNPs shows a typical optical absorption peak at 3KeV. Peaks of
305 silver element were obtained at 3keV from the particle of *C. carandas* leaf mediated obtained
306 AgNPs. Few weaker peaks were observed which corresponding to O and C also found.

307 **XRD**

308 XRD pattern was evaluated to resolve the width, peak position and peak intensity in 2 θ
309 spectrum ranging from 20° to 80° as depicted in Fig 3 (B). Characteristic peaks at 38.01, 44.13,
310 64.46, 77.40; Bragg reflections corresponding to [111], [200], [220] and [311] lattice plans of
311 FCC structure (JCPDS File No. 04–0783) of AgNPs were observed. This pattern shows the
312 crystalline structure of AgNPs, size of AgNPs was calculated by full width at half-maximum
313 (FWHM) data with the Scherrer formula $D=K \lambda / \beta \cos\theta$ was estimated to be 25.4 nm. Where

314 k = constant, λ = X-ray wavelength, β = angular FWHM, θ = Bragg's diffraction angle and D =
315 crystalline size of diffraction angle θ .

316 In addition, three unassigned peaks appeared at 27.99°, 32.13° and 46.28°. These peaks were
317 weaker than those of silver. This may be due to the bioorganic compounds occurring on the
318 surface of AgNPs. Appearances of these peaks are due to the presence of phytochemical
319 compounds in the leaf extracts. The stronger planes indicate silver as a major constituent in the
320 biosynthesis.

321 FTIR

322 The FTIR spectrum of AgNPs shows major absorption band around 440.02, 479.57,
323 548.00, 1104.68, 1383.22, 1443.38, 1621.55, 2921.60, 3419.99 cm^{-1} and the crude *C. carandas*
324 leaf extract shows absorption spectra on 780.44, 1105.57, 1315.55, 1386.44, 1443.56, 1617.79,
325 2922.97, 3421.32 cm^{-1} depicted in Fig 4 (D). The peak on 440.02 was due to aryl disulphide
326 stretches, 479.57 cm^{-1} was due to polysulphide stretches, 548 due to C-I stretches and 1104.68
327 and 1105.57 were –C-O- stretching vibration of alcohol and phenol, 1443.38 and 1443.56 cm^{-1}
328 were –C=C- aromatic structures, 1621.55 and 1617.79 were the -C=C- alkene group. Peaks
329 2921.60, and 2922.97 cm^{-1} were -CH₃ group and the band on 3419.99 and 3421.32 cm^{-1} were
330 the normal polymeric stretch of hydroxyl (OH) group. The absorption band is due to the
331 vibration effect of the alkaloids, terpenoids and flavonoids present in the plant extract and plays
332 crucial role in capping and stabilization of AgNPs. The band shift of hydroxyl group in the
333 FTIR spectra confirmed the binding of Ag⁺ to the OH group. All the changes in peak support
334 the impact of functional group in *C. carandas* leaf extract as reducing and stabilizing agents to
335 synthesize AgNPs. Some peaks appeared in the FTIR spectrum of leaf and disappeared in
336 AgNPs spectrum. The disappearance of peaks suggests that phytochemical present in the
337 extract involved in the reduction of AgNPs [29].

338

339 **HR-TEM**

340 High resolution Transmission electron microscope determined the morphology, shape
341 and size of bio fabricated AgNPs as shown in the Fig 4 (A). we have analyzed TEM micrograph
342 using Image J software and from the analysis we have found the particles was polydispersed
343 and predominantly found to be spherical with the average diameter of approximately 14nm
344 were determined through the histogram obtained Fig 4 (B). SAED pattern image of AgNPs
345 revealed the diffraction rings from inside to outside, could be indexed as [111, 200, 220, 311]
346 reflections respectively with some bright spots due to Bragg's reflection, corresponding to face-
347 centered cubic (fcc) silver was depicted in Fig 4 (C).

348 **Antibacterial activity**

349 Antibacterial activity of synthesized AgNPs was evaluated against Gram positive and Gram
350 negative uropathogens such as *S. aureus*, *E. coli* and *P. aeruginosa*. The clear zone was
351 gradually increased based on the dose dependent manner as shown in the Table 1 and Fig 5.
352 The well diffusion assay also performed for comparative study of crude extract, AgNO₃
353 solution, Standard antibiotic Ciprofloxacin (50µg/mL), AgNPs, DMSO as a solvent control as
354 shown in Fig. 6 and these results were depicted in the Table 2.

355 **Minimum Inhibitory (MIC) and Minimum Bactericidal**

356 **Concentration (MBC)**

357 After 24 h of incubation at 37°C, turbidity was noticed in the *E. coli* AMB4 well plates
358 20 and 40 µg/mL containing silver nanoparticles indicating the growth of bacteria. Whereas in
359 the concentrations of 60, 80, 100, 120, 140, 160 µg/mL, no turbidity was seen, indicating the
360 inhibition of bacterial growth (Fig 7). Highest concentration 160 µg/mL of AgNPs, OD_{590nm}
361 (0.18) shows 99% inhibition, whereas the minimum inhibitory concentration was found to be
362 60 µg/mL, OD_{590nm} (0.63) shows 97% inhibition towards *E. coli* AMB4. The MHA plates also

363 show no bacterial growth from the concentrations of 60, 80, 100, 120, 140, 160 $\mu\text{g}/\text{mL}$, hence
364 confirming it as bactericidal.

365 Similarly, *S. aureus* AMB6 and *P. aeruginosa* AMB5 well plate containing AgNPs
366 showed turbidity in 20 $\mu\text{g}/\text{mL}$, whereas no turbidity was seen in the concentrations of 40, 60,
367 80, 100, 120, 140, 160 $\mu\text{g}/\text{mL}$ containing AgNPs indicating the bacterial inhibition (Fig 7).
368 Highest concentration 160 $\mu\text{g}/\text{mL}$ of AgNPs, $\text{OD}_{590\text{nm}}$ (0.22) shows 99% inhibition for *S.*
369 *aureus* AMB6 and highest concentration 160 $\mu\text{g}/\text{mL}$ of AgNPs, $\text{OD}_{590\text{nm}}$ (0.25) shows 99.5%
370 inhibition for *Pseudomonas aeruginosa* AMB5. Therefore, MIC of *S. aureus* AMB6 was found
371 to be 40 $\mu\text{g}/\text{mL}$ with $\text{OD}_{590\text{nm}}$ (0.69) shows 97% inhibition and MIC of *P. aeruginosa* AMB5
372 was found to be 40 $\mu\text{g}/\text{mL}$, $\text{OD}_{590\text{nm}}$ (0.60) shows 97% inhibition. The MHA plates also show
373 no bacterial growth from the concentrations of 40, 60, 80, 100, 120, 140, 160 $\mu\text{g}/\text{mL}$, hence
374 confirming it as bactericidal.

375 **Synergistic effect of silver nanoparticles with commercial** 376 **antibiotics**

377 In the present work, 3 commercial antibiotics were tested alone and with AgNPs against
378 the test pathogens. AgNPs alone showed antimicrobial activity and commercial antibiotics also
379 showed antimicrobial activity when the AgNPs is combined with the commercial antibiotics,
380 the antimicrobial activity increased with increased fold as it was evidenced in Table.3.
381 Maximum increase in fold area was 3.84 and 2.3 against trimethoprim (Table 3). The
382 synergistic antimicrobial activity against *P. aeruginosa* was better than that of *E. coli* and *S.*
383 *aureus*. Maximum increase in fold was 3.84 against trimethoprim 1.04 for *E. coli* while it was
384 2.3 for *S. aureus* against trimethoprim (Table 3)

385

386

387 **Bacterial biofilm potential**

388 In our study, the biofilm forming ability was verified by test tube method. The test tube
389 base contains the adhered layer of uropathogens. *P. aeruginosa* forms a strong biofilm mat than
390 another organism. The biofilms were analyzed quantitatively to check the potential biofilm
391 formers, *P. aeruginosa* shows $OD_C (0.1784) < OD (3.045)$ however *S. aureus* also produce
392 strongly adherent biofilm layer $OD_C (0.1784) < OD (3.1074)$, *E. coli* shows an $OD_C (0.1784)$
393 $< OD (3.012)$ confirms that it is a strong biofilm former.

394 **Biofilm inhibition in AgNPs coated catheter**

395 AgNPs coated catheter (Fig 8) was evaluated for the anti-biofilm activity against the
396 uropathogens. Uropathogens adhered to the surface of catheter was treated with different
397 concentration of AgNPs and subjected to microscopic analysis. Under the microscopic
398 observation tightly adhered cells are gradually dispersed depending upon the concentration of
399 NPs compare whereas control showed an adhered mat formation as shown in S1 Fig. Viability
400 and disruption of biofilm mat after AgNPs treatment was analyzed by fluorescence microscopy,
401 showed an abruption of biofilm on AgNPs coated catheters as shown in S2 Fig. Dense biofilm
402 mat on uncoated catheter using an acridine orange staining method. In quantitative assay,
403 highest concentration of AgNPs coated catheter showed the highest level of inhibition. The
404 inhibition of *Pseudomonas aeruginosa* $85.8 \pm 1.450\%$ was slightly higher than the *S. aureus*
405 $82.8 \pm 1.83\%$ whereas the inhibition percentage of *E. coli* $71.4 \pm 1.25\%$ become lesser than the
406 other two test pathogen. Percentage of inhibition was calculated and shown in Fig. 9.

407 **Antibacterial activity of AgNPs coated urinary catheter**

408 Antibacterial activity of AgNPs coated urinary catheter and uncoated catheter as shown
409 in the Fig.8 was evaluated where $40\mu\text{g/mL}$ of AgNPs coated catheter exhibits antibacterial
410 activity with the value of 17 ± 0.4 , 21 ± 0.3 , and 13 ± 0.1 for *S. aureus* AMB6, *E. coli* AMB4, and

411 *P. aeruginosa* AMB 5, respectively. Urinary catheter impregnated with AgNPs shows ZOI
412 against uropathogens whereas uncoated catheter shows no zone of inhibition (Table 2).

413 **SEM analysis of Urinary catheter**

414 SEM analysis of AgNPs coated catheter Fig. 10 (A) clearly shows the strong overlaying of
415 AgNPs on the catheter surface and uncoated catheter Fig 10 (B) shows a clear image of catheter
416 surface. Further, SEM imaging was done on the AgNPs coated catheter inoculated with strong
417 biofilm former *E. coli* AMB4 Fig 10 (D) states the biofilm mat formed by the *E. coli* AMB4
418 was disturbed due to the activity of AgNPs and Fig 10 (C) clearly shows the dense biofilm mat
419 on the surface of the uncoated catheter inoculated with *E. coli* AMB4 which proves that *E. coli*
420 AMB4 is a strong biofilm former. Incorporation of urinary catheter (biomedical devices) with
421 AgNPs provide better biocompatibility.

422 **Discussions**

423 Uropathogens are the major cause of UTI with their biofilm formation. These
424 uropathogens are notorious and perpetuating. They become combat against wide range of
425 antibiotics and environmental stress such as host immune response. They are difficult to treat
426 and eradicate [30]. The major toughness of biofilm is architecture EPS, quorum sensing (QS)
427 activity. The over production of EPS leads to resistant against antibiotic and another crucial
428 factor is QS (construction of wild type architecture) it increases the stability against oxidative
429 and osmotic stresses of biocide [31] Milan et al. [32] states that nosocomial acquired UTI
430 shows high level of resistant than community acquired UTI show the patient indwelling
431 catheters shows high risk of UTI. Due to its biocompatibility and backdrop of antimicrobial
432 resistant create the thirst of seeking naive therapeutic despite of antibiotic [33]. The plant
433 derived drug compiled with nanotechnology wrap out the resistance against Uropathogens. In
434 this present study, *C. carandas* leaf extract was subjected to synthesize silver nanoparticle,

435 with potent antibacterial and antibiofilm activity. The choice of green synthesis of NPs was
436 due to their capping capability and stability. Biosynthesized NPs are facile; cost of effective,
437 fast, non-toxic, possessing well defined morphology and uniformity in size [34]. Ag⁺ capped
438 with the phytomolecules present in the plant enhanced the antimicrobial activity. Fig 2 (A-D)
439 demonstrates the absorption spectra of SPR for the optimization of AgNPs synthesis under
440 distinct parameters viz. pH, crude extract concentration, Ag ion concentration and incubation
441 time for analysis. These results provide for evaluating the reaction parameter and optimized
442 conditions for NPs synthesis [35] Ibrahim [36] stated that, reaction mixture color and SPR
443 intensity which are pH dependent.

444 In our study, acidic and alkaline pH shows weak absorbance peak. However, strong
445 intense peak was observed in pH 9, agglomeration of reaction was happened. The neutral pH
446 7 typically increased the absorbance peak and provide a favorable environment. Crude
447 concentration is noteworthy due to their phytochemical stabilizing agents. The raising of
448 absorption peak was noticed in in 1.25ml of extract concentration. Whereas the addition of
449 higher crude concentration lead to decreased absorbance peak [37]. The absorption peaks were
450 gradually increased with the increased metal concentration which may be attributed by
451 longitudinal vibrations [38]. Optimized parameters of AgNPs have 1.25mM concentration of
452 AgNO₃, 1.25mL of substrate concentration with pH7 supported the maximum formation of
453 AgNPs within 20 minutes time period. The color change of the heterogeneous reaction mixture
454 observed at 410nm due to their electron excitation similar observation [39]. FTIR peak of our
455 study was in accordance to Pavia et al. 2009 [40], the peaks ranging from 3200-3600 cm⁻¹ are
456 related to the O-H and -NH₂ stretching vibrations and suggest that hydroxyl and carbonyl
457 groups may responsible for the synthesis and stabilization of AgNPs [41], the peak at 2921.60
458 and 2922.97 are assigned to C-H stretching [40]. According to Mariselvam et al. [42]
459 absorption band ranging from 1700-1600 cm⁻¹ in the spectra confirms the formation of AgNPs.

460 The bands observed at 1383.22 cm^{-1} and 1386.44 cm^{-1} corresponds to the C-N stretching
461 vibration of aromatic amine [43]. The presence of amines or alcohols or phenols represents the
462 polyphenols capped by AgNPs [44,45]. The shifting peak up and down reveals the synthesis
463 of AgNPs. Biomolecules in *C. carandas* leaf extract is responsible for the stabilization of
464 AgNPs [46]. The FTIR analysis speaks the stretch band and bond of AgNPs, the presence of
465 potential biomolecules with Ag attachment leads stabilization and capping [3,19]. Due to their
466 surface adhered potential biomolecules, green mediated AgNPs shows the higher anti-bacterial
467 and anti-biofilm activity [47]. The size and shape of AgNPs plays a major role in bactericidal
468 activity [48]. XRD analysis revealed the crystalline nature of AgNPs presence of silver
469 confirmed by the diffraction pattern. These XRD patterns reported in earlier studies Saratale et
470 al. [49] was accordance with our results. EDX profile outcomes exhibits the strong signal for
471 silver approximately at 3KeV due to the SPR which is identical to Ramar et al. [50] and
472 Magudapathy et al. [51] for the production of leaf extract mediated synthesis AgNPs. The
473 structure and size of NPs were concluded as spherical and polydispersed with the approximate
474 size of 14nm was confirmed by HR-TEM analysis [52]. SAED pattern of AgNPs was shown
475 in the Fig 4C. Further ring like diffraction pattern indicates that the particles are crystalline
476 [53]. During recent years, undesirable consequence effect of catheter related UTI infections
477 lead to the increased mortality [54]. Application of AgNPs shows the efficient antimicrobial
478 activity and that are justifiable tool for evading indwelling catheter related infections.
479 Medically implantable devices coated with AgNPs which are requisite factor for evading the
480 bacterial adherence and agglomeration of biofilm [55] in this investigation reported that, *E.*
481 *coli* (71.4%), *S. aureus* (82.8%), *P. aeruginosa* (85.8%) these nosocomial clinical pathogens
482 are prevalent in formation of biofilm. These results were similar to Sharma et al. [56] and
483 Kamarudheen and Rao [57]. The AgNPs embedded catheter shows antimicrobial activity
484 against uropathogens which may due to their size and inhibition capacity that makes the drug

485 resistant uropathogens susceptible [58]. The commercial catheters coated with AgNPs (Fig 8)
486 creates the efficiency against the UTI. Urinary catheters are the major cause of biofilm
487 formation in urinary tract results in nosocomial infection [59]. Techniques followed to coat
488 urinary catheter as layer by layer for enzyme coating, impregnation of antimicrobial agents
489 [60], polycationic nanosphere coating [61], impregnation of complex molecules [62]. In recent
490 years, impregnation of urinary catheter with silver is under practice [63]. AgNPs is a fast and
491 promising strategy for bactericidal coating on silicone based medical devices [64]. In recent
492 years, there is rise in mortality rate associated with catheter associated urinary tract infection
493 [65]. Therefore, it is important to coat the medical devices with antimicrobial agents. AgNPs
494 are excellent tool for avoiding catheter associated UTI [55]. The solid surface provides a strong
495 anchoring habitation for bacteria to form biofilm, similarly biofilm is formed on the surface of
496 implant device, which protects the bacteria from antibiotic action and cause several infections
497 [66]. Additionally, functionalized, immobilized and surface modified AgNPs embedded on
498 surface of implants are inhibiting bacterial adhesion and *icaAD* transcription in implants [67].

499 The AgNPs reduces the encrustation of obstinate biofilm and ruptures and disintegrate
500 the biofilm mat and shows bactericidal activity against uropathogens. The coated catheter
501 shows antibacterial, anti-EPS and anti-quorum sensing activity of uropathogens and end up the
502 pathogens into avirulent and disrupt the biofilm [68]. Fluorescence microscopy (S₂ Fig.) shows
503 the bacterial biofilm formation over uncoated urinary catheter by uropathogens whereas
504 biofilm disruption was observed in the AgNPs coated urinary catheter exposed to
505 uropathogens. Differentiation of live and dead cells was exhibited by fluorescence with
506 intercalation of Acridine orange[69]. AgNPs are responsible for the anti-cancer, anti-oxidant,
507 anti-microbial activity. The *in-vitro* studies show efficient result against uropathogens by using
508 AgNPs coated catheters. Scanning Electron Microscopy (Fig 10) was employed to identify the

509 biofilm formation and destruction in surface modified and unmodified catheters using AgNPs
510 exposed to uropathogens.

511 The AgNPs have tremendous advantage for biological applications over the bulk metal
512 owing to its size that enables the NPs to facilitate to anchor in to the micro cell (bacteria)
513 components [70]. AgNPs causes physical damage to the cell components leads to killing of
514 bacteria (Fig 11). Because of the cell wall, architecture, thickness varies, AgNPs antibacterial
515 action is associated with gram positive and gram-negative bacteria [71]. Plenty of hypothesis
516 that have been proposed, the antibacterial mechanism action has yet to be definitively
517 established. The antibacterial mechanism (Fig 11) that we postulated based on the existing
518 literature may be described as follows; 1) plant mediated AgNPs adherence to the membrane
519 of cell forms an electrostatic interaction results in the leakage of internal substances; 2) Ag⁺
520 ions or AgNPs interact with the sulfhydryl group of enzymes and proteins [72] and inhibit the
521 enzymatic and protein activity; 3) Cellular toxicity induced by AgNPs is triggered by reactive
522 oxygen species (ROS) and free radicals, which destroys internal organelles and causes cell
523 death, lipid peroxidation, and DNA damage ; 4) AgNPs interact with the ribosome and inhibit
524 the translation process in the cell. The high surface area of AgNPs in generating silver ions
525 explain the mechanism of AgNPs action. In the presence of oxygen and proton, aqueous AgNPs
526 were oxidized producing silver ions when the particle dissolves [73]. The toxicity of smaller
527 or anisotropic AgNPs with greater surface area was higher [74]. For improved antibacterial
528 action, the greatest concentration of silver ions, quickest release of silver ions and greater
529 surface area of silver ions are evaluated [75]. AgNPs antibacterial action is mostly owing to
530 their capacity to generate ROS and free radical [76]. These free radicals attached to the cell
531 wall of bacteria and generate pore, these pores ultimately cause cell death [77]. Moreover,
532 production free radical and high levels of reactive oxygen species (ROS) are also a precise
533 mechanism of AgNPs to inhibit bacterial by apoptosis and DNA damage [78]. There are

534 different proposed mechanisms for antimicrobial activity of AgNPs. AgNPs (positively
535 charged) can easily interact with negatively charged cell membrane which enhances the
536 antibacterial activity [79]. The charges in the cell can facilitate the attraction of AgNPs for
537 attachment on to the cell membrane [80]. AgNPs also destabilize the ribosomes, mitochondrial
538 dysfunction and inhabit the electron transport chain [67]. AgNPs causes damages to bacteria
539 by interfering the function of DNA replication [81], cell division and respiratory chain [82].
540 Because of the combination of cell wall components and AgNPs charges, the effect of AgNPs
541 on gram positive bacteria is smaller than on gram negative bacteria [67]. The killing of bacteria
542 directed through several phenomenon like penetration of AgNPs in to membrane, surface area
543 in contact, reach cytoplasm, ribosomes, interaction with cellular structures and biomolecules
544 by several process [73].

545 Our study proposed the antibiofilm mechanism (Fig 12) of AgNPs can be summarized
546 as follows: 1) AgNPs has electrostatic interaction with the cells and disturb the biofilm
547 formation; 2) AgNPs degrade the EPS formation and breaks the biofilm mat; 3) AgNPs inhibits
548 the signal produced by the bacteria, thereby inhibiting the biofilm formation; 4) AgNPs
549 penetrate the biofilm and creates anti-adherence which ultimately cause the leakage of cellular
550 contents. Bacterial adhesion, biofilm development and biofilm integrity, as well as internal
551 communication, are all aided by extracellular DNA (eDNA) [83]. eDNA acts as an excellent
552 target to eliminate bacterial biofilm [84]. eDNA is polyanionic nature and electrostatic contact
553 is mostly mediated by AgNPs that are positively charged. Through short range hydrophobic
554 and Vander Waals force, silver ions interact with the oxygen and nitrogen atoms of DNA bases
555 [85-87]. Electrostatic interaction, on the other hand, has an impact on them. In biofilms, AgNPs
556 interact with both cellular and extracellular RNA [88,89]. Studies shows that AgNPs interact
557 with the small regulatory RNA, reduced biofilm and fibronectin binding by altering the RNA
558 profile of *S. aureus* [88]. Earlier, several reports on antibiofilm activity of AgNPs against

559 several bacteria shows a promising activity [67] [90,91]. Among all AgNPs interactions,
560 AgNPs with *Pseudomonas putida* shows an innovative finding to arrest biofilm [67,90,91].
561 Extracellular proteins are the essential component of biofilm. AgNPs interact with these protein
562 and extracellular polysaccharide secreted in biofilm [92]. Several studies shows that AgNPs
563 reduced the synthesis of extra polysaccharides in *P. aeruginosa* and *S. epidermidis* biofilm and
564 their mechanism was unknown [93].

565 The leaf extract of *C. carandas* is said to contain a lot of flavonoids [16]. AgNPs
566 synthesized using *C. carandas* leaf extract showed antibacterial activity [94]. The mechanism
567 for AgNPs synthesis includes; silver ions have positive charge that attracts the functional group
568 of phytomolecules found in plants. The phytomolecules such as flavonoids, alcoholic and
569 phenolic compounds, tannins, terpenoids, glycosides act as a reducing agent and reducing Ag⁺
570 ion to Ago [95].

571 Hence, an overall mechanism proposed that phytochemical mediated synthesized
572 AgNPs will open a new avenue to use as antibacterial and antibiofilm candidate after
573 embedding in to implants.

574 Conclusion

575 Even though, many literatures were available for silver nanoparticles, silver is gaining
576 its attention because of its antimicrobial properties. Synthesis of AgNPs using the leaf extract
577 will provide an ecofriendly, cheap, easily available and non-toxic. In the present study, green
578 synthesis of AgNPs was done using *C. carandas* leaf extract, AgNPs exhibited excellent
579 antibacterial activity towards *S. aureus* AMB6 and also showed excellent synergistic activities
580 against *P. aeruginosa* AMB 5, AgNPs coated urinary catheter showed highest biofilm
581 inhibition in *Pseudomonas aeruginosa* AMB5 $85.8 \pm 1.450\%$. The potential of AgNPs in
582 inhibiting the biofilm formation supports it as a potential application for AgNPs coated medical
583 devices. Thus, the present study helps in disclosing the biomaterial coating acts as a preventive

584 shield against uropathogens and it is long lasting, feasible technique and it act as promising
585 treatment for UTI and nosocomial infections.

586 **Conflicts of interest**

587 The authors have no conflicts of interest to declare. All co-authors have seen and agree with
588 the contents of the manuscript and there is no financial interest to report.

589 **Authors Contributions**

590 PV came up with the idea and participated in the design, preparation of AgNPs, and writing of
591 the manuscript. HBHR performed the characterization of nanoparticles. RD participated in
592 culturing, antibacterial activity, anti-biofilm activity, and other biochemical assays. TS, SM
593 and RP participated in the coordination of this study. All authors read and approved the final
594 manuscript.

595 **Acknowledgements**

596 The authors thank the Vice-Chancellor and Registrar of Alagappa University for providing the
597 research facilities.

598 **Reference:**

- 599 1. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and
600 economic costs. *The American journal of medicine* 113: 5-13.
- 601 2. Nicolle LE, Yoshikawa TT (2000) Urinary tract infection in long-term-care facility residents.
602 *Clinical infectious diseases* 31: 757-761.
- 603 3. Divya M, Kiran GS, Hassan S, Selvin J (2019) Biogenic synthesis and effect of silver
604 nanoparticles (AgNPs) to combat catheter-related urinary tract infections. *Biocatalysis*
605 and agricultural biotechnology 18: 101037.

- 606 4. Sileika TS, Kim H-D, Maniak P, Messersmith PB (2011) Antibacterial performance of
607 polydopamine-modified polymer surfaces containing passive and active components.
608 ACS applied materials & interfaces 3: 4602-4610.
- 609 5. Siddiq DM, Darouiche RO (2012) New strategies to prevent catheter-associated urinary tract
610 infections. Nature Reviews Urology 9: 305-314.
- 611 6. Warren JW (1997) Catheter-associated urinary tract infections. Infectious disease clinics of
612 North America 11: 609-622.
- 613 7. Doll K, Jongstaphongpun KL, Stumpp NS, Winkel A, Stiesch M (2016) Quantifying
614 implant-associated biofilms: Comparison of microscopic, microbiologic and
615 biochemical methods. Journal of microbiological methods 130: 61-68.
- 616 8. Singha P, Locklin J, Handa H (2017) A review of the recent advances in antimicrobial
617 coatings for urinary catheters. Acta biomaterialia 50: 20-40.
- 618 9. Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, et al. (2016) Biofilms: an
619 emergent form of bacterial life. Nature Reviews Microbiology 14: 563-575.
- 620 10. Geetha AR, George E, Srinivasan A, Shaik J (2013) Optimization of green synthesis of
621 silver nanoparticles from leaf extracts of *Pimenta dioica* (Allspice). The Scientific
622 World Journal 2013.
- 623 11. Devi JS, Bhimba BV, Ratnam K (2012) In vitro anticancer activity of silver nanoparticles
624 synthesized using the extract of *Gelidiella* sp. Int J Pharm Pharm Sci 4: 710-715.
- 625 12. Rai M, Ingle AP, Gade A, Duran N (2015) Synthesis of silver nanoparticles by *Phoma*
626 *gardeniae* and in vitro evaluation of their efficacy against human disease- causing
627 bacteria and fungi. IET nanobiotechnology 9: 71-75.
- 628 13. Morton JF (1987) Fruits of warm climates: JF Morton.

- 629 14. Verma K, Shrivastava D, Kumar G (2015) Antioxidant activity and DNA damage inhibition
630 in vitro by a methanolic extract of *Carissa carandas* (Apocynaceae) leaves. Journal of
631 Taibah University for Science 9: 34-40.
- 632 15. Verma S, Chaudhary H (2011) Effect of *Carissa carandas* against clinically pathogenic
633 bacterial strains. Journal of Pharmacy Research 4: 3769.
- 634 16. Sawant RS, Godghate A (2013) Comparative studies of phytochemical screening of *Carissa*
635 *carandus* Linn. Asian J Plant Sci Res 3: 21-25.
- 636 17. Pathak G, Singh S, Singhal M, Singh J, Hussain Y, et al. (2021) Pharmacology of *Carissa*
637 *carandas* leaf extract: anti-proliferative, antioxidant and antimicrobial investigation.
638 Plant Biosystems-An International Journal Dealing with all Aspects of Plant Biology
639 155: 543-556.
- 640 18. Agarwal T, Singh R, Shukla AD, Waris I (2012) In vitro study of antibacterial activity of
641 *Carissa carandas* leaf extracts. Asian J Plant Sci Res 2: 36-40.
- 642 19. Kora AJ, Sashidhar R, Arunachalam J (2010) Gum kondagogu (*Cochlospermum*
643 *gossypium*): a template for the green synthesis and stabilization of silver nanoparticles
644 with antibacterial application. Carbohydrate Polymers 82: 670-679.
- 645 20. Parvekar P, Palaskar J, Metgud S, Maria R, Dutta S (2020) The minimum inhibitory
646 concentration (MIC) and minimum bactericidal concentration (MBC) of silver
647 nanoparticles against *Staphylococcus aureus*. Biomaterial Investigations in Dentistry 7:
648 105-109.
- 649 21. Agarwala M, Barman T, Gogoi D, Choudhury B, Pal AR, et al. (2014) Highly effective
650 antibiofilm coating of silver-polymer nanocomposite on polymeric medical devices
651 deposited by one step plasma process. Journal of Biomedical Materials Research Part
652 B: Applied Biomaterials 102: 1223-1235.

- 653 22. Christensen GD, Simpson WA, Younger J, Baddour L, Barrett F, et al. (1985) Adherence
654 of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model
655 for the adherence of staphylococci to medical devices. *Journal of clinical microbiology*
656 22: 996-1006.
- 657 23. Saxena S, Banerjee G, Garg R, Singh M (2014) Comparative study of biofilm formation in
658 *Pseudomonas aeruginosa* isolates from patients of lower respiratory tract infection.
659 *Journal of clinical and diagnostic research: JCDR* 8: DC09.
- 660 24. Thomas R, Soumya K, Mathew J, Radhakrishnan E (2015) Inhibitory effect of silver
661 nanoparticle fabricated urinary catheter on colonization efficiency of Coagulase
662 Negative Staphylococci. *Journal of Photochemistry and Photobiology B: Biology* 149:
663 68-77.
- 664 25. Merritt JH, Kadouri DE, O'Toole GA (2006) Growing and analyzing static biofilms.
665 *Current protocols in microbiology*: 1B. 1.1-1B. 1.17.
- 666 26. Cady NC, McKean KA, Behnke J, Kubec R, Mosier AP, et al. (2012) Inhibition of biofilm
667 formation, quorum sensing and infection in *Pseudomonas aeruginosa* by natural
668 products-inspired organosulfur compounds. *PLoS One* 7: e38492.
- 669 27. Dhas TS, Kumar VG, Karthick V, Angel KJ, Govindaraju K (2014) Facile synthesis of
670 silver chloride nanoparticles using marine alga and its antibacterial efficacy.
671 *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 120: 416-420.
- 672 28. Djeribi R, Bouchloukh W, Jouenne T, Menea B (2012) Characterization of bacterial
673 biofilms formed on urinary catheters. *American journal of infection control* 40: 854-
674 859.
- 675 29. Anandalakshmi K, Venugobal J (2017) Green synthesis and characterization of silver
676 nanoparticles using *Vitex negundo* (Karu Nochchi) leaf extract and its antibacterial
677 activity. *Med Chem* 7: 218-225.

- 678 30. Høiby N, Ciofu O, Bjarnsholt T (2010) *Pseudomonas aeruginosa* biofilms in cystic fibrosis.
679 Future microbiology 5: 1663-1674.
- 680 31. Wai SN, Mizunoe Y, Takade A, Kawabata S-I, Yoshida S-I (1998) *Vibrio cholerae* O1
681 strain TSI-4 produces the exopolysaccharide materials that determine colony
682 morphology, stress resistance, and biofilm formation. Applied and environmental
683 microbiology 64: 3648-3655.
- 684 32. Milan PB, Ivan IM (2009) Catheter-associated and nosocomial urinary tract infections:
685 antibiotic resistance and influence on commonly used antimicrobial therapy.
686 International urology and nephrology 41: 461.
- 687 33. Gurunathan S, Park JH, Han JW, Kim J-H (2015) Comparative assessment of the apoptotic
688 potential of silver nanoparticles synthesized by *Bacillus tequilensis* and *Calocybe*
689 *indica* in MDA-MB-231 human breast cancer cells: targeting p53 for anticancer
690 therapy. International journal of nanomedicine 10: 4203.
- 691 34. Ahmed S, Ahmad M, Swami BL, Ikram S (2016) A review on plants extract mediated
692 synthesis of silver nanoparticles for antimicrobial applications: a green expertise.
693 Journal of advanced research 7: 17-28.
- 694 35. Ahmed S, Saifullah, Ahmad M, Swami BL, Ikram S (2016) Green synthesis of silver
695 nanoparticles using *Azadirachta indica* aqueous leaf extract. Journal of radiation
696 research and applied sciences 9: 1-7.
- 697 36. Ibrahim HM (2015) Green synthesis and characterization of silver nanoparticles using
698 banana peel extract and their antimicrobial activity against representative
699 microorganisms. Journal of Radiation Research and Applied Sciences 8: 265-275.
- 700 37. Kalpana D, Han JH, Park WS, Lee SM, Wahab R, et al. (2019) Green biosynthesis of silver
701 nanoparticles using *Torreya nucifera* and their antibacterial activity. Arabian Journal of
702 Chemistry 12: 1722-1732.

- 703 38. Prathna T, Chandrasekaran N, Raichur AM, Mukherjee A (2011) Biomimetic synthesis of
704 silver nanoparticles by Citrus limon (lemon) aqueous extract and theoretical prediction
705 of particle size. *Colloids and Surfaces B: Biointerfaces* 82: 152-159.
- 706 39. Medda S, Hajra A, Dey U, Bose P, Mondal NK (2015) Biosynthesis of silver nanoparticles
707 from Aloe vera leaf extract and antifungal activity against *Rhizopus* sp. and *Aspergillus*
708 sp. *Applied Nanoscience* 5: 875-880.
- 709 40. Pavia DL, Lampman GM, Kriz GS, Vyvyan J (2009) *Introduction to Spectroscopy*, Brooks.
710 Cole Cengage Learning: 381-417.
- 711 41. Mohanta YK, Biswas K, Jena SK, Hashem A, Abd_Allah EF, et al. (2020) Anti-biofilm
712 and antibacterial activities of silver nanoparticles synthesized by the reducing activity
713 of phytoconstituents present in the Indian medicinal plants. *Frontiers in Microbiology*
714 11: 1143.
- 715 42. Mariselvam R, Ranjitsingh A, Nanthini AUR, Kalirajan K, Padmalatha C, et al. (2014)
716 Green synthesis of silver nanoparticles from the extract of the inflorescence of *Cocos*
717 *nucifera* (Family: *Arecaceae*) for enhanced antibacterial activity. *Spectrochimica Acta*
718 *Part A: Molecular and Biomolecular Spectroscopy* 129: 537-541.
- 719 43. Vigneshwaran N, Ashtaputre N, Varadarajan P, Nachane R, Paralikal K, et al. (2007)
720 Biological synthesis of silver nanoparticles using the fungus *Aspergillus flavus*.
721 *Materials letters* 61: 1413-1418.
- 722 44. Vanaja M, Annadurai G (2013) *Coleus aromaticus* leaf extract mediated synthesis of silver
723 nanoparticles and its bactericidal activity. *Applied nanoscience* 3: 217-223.
- 724 45. Shah M, Nawaz S, Jan H, Uddin N, Ali A, et al. (2020) Synthesis of bio-mediated silver
725 nanoparticles from *Silybum marianum* and their biological and clinical activities.
726 *Materials Science and Engineering: C* 112: 110889.

- 727 46. Ahmad N, Sharma S (2012) Green synthesis of silver nanoparticles using extracts of
728 *Ananas comosus*.
- 729 47. Singh P, Kim Y-J, Zhang D, Yang D-C (2016) Biological synthesis of nanoparticles from
730 plants and microorganisms. *Trends in biotechnology* 34: 588-599.
- 731 48. Leuck A-M, Johnson JR, Hunt MA, Dhody K, Kazempour K, et al. (2015) Safety and
732 efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-
733 associated bacteriuria: a pilot randomized clinical trial. *American journal of infection*
734 *control* 43: 260-265.
- 735 49. Saratale RG, Benelli G, Kumar G, Kim DS, Saratale GD (2018) Bio-fabrication of silver
736 nanoparticles using the leaf extract of an ancient herbal medicine, dandelion
737 (*Taraxacum officinale*), evaluation of their antioxidant, anticancer potential, and
738 antimicrobial activity against phytopathogens. *Environmental Science and Pollution*
739 *Research* 25: 10392-10406.
- 740 50. Ramar M, Manikandan B, Marimuthu PN, Raman T, Mahalingam A, et al. (2015) Synthesis
741 of silver nanoparticles using *Solanum trilobatum* fruits extract and its antibacterial,
742 cytotoxic activity against human breast cancer cell line MCF 7. *Spectrochimica Acta*
743 *Part A: Molecular and Biomolecular Spectroscopy* 140: 223-228.
- 744 51. Magudapathy P, Gangopadhyay P, Panigrahi B, Nair K, Dhara S (2001) Electrical transport
745 studies of Ag nanoclusters embedded in glass matrix. *Physica B: Condensed Matter*
746 299: 142-146.
- 747 52. Ingle A, Rai M, Gade A, Bawaskar M (2009) *Fusarium solani*: a novel biological agent for
748 the extracellular synthesis of silver nanoparticles. *Journal of Nanoparticle Research* 11:
749 2079-2085.

- 750 53. Ahmad N, Sharma S, Alam MK, Singh V, Shamsi S, et al. (2010) Rapid synthesis of silver
751 nanoparticles using dried medicinal plant of basil. *Colloids and Surfaces B:*
752 *Biointerfaces* 81: 81-86.
- 753 54. Nicolle LE (2012) Urinary catheter-associated infections. *Infectious Disease Clinics* 26:
754 13-27.
- 755 55. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, et al. (2005) The bactericidal
756 effect of silver nanoparticles. *Nanotechnology* 16: 2346.
- 757 56. Sharma M, Yadav S, Chaudhary U (2009) Biofilm production in uropathogenic *Escherichia*
758 *coli*. *Indian Journal of Pathology and Microbiology* 52: 294.
- 759 57. Kamarudheen N, Rao KB (2019) Fatty acyl compounds from marine *Streptomyces*
760 *griseoincarnatus* strain HK12 against two major bio-film forming nosocomial
761 pathogens; an in vitro and in silico approach. *Microbial pathogenesis* 127: 121-130.
- 762 58. Li W-R, Xie X-B, Shi Q-S, Zeng H-Y, You-Sheng O-Y, et al. (2010) Antibacterial activity
763 and mechanism of silver nanoparticles on *Escherichia coli*. *Applied microbiology and*
764 *biotechnology* 85: 1115-1122.
- 765 59. Ivanova K, Fernandes MM, Mendoza E, Tzanov T (2015) Enzyme multilayer coatings
766 inhibit *Pseudomonas aeruginosa* biofilm formation on urinary catheters. *Applied*
767 *microbiology and biotechnology* 99: 4373-4385.
- 768 60. Saini H, Chhibber S, Harjai K (2016) Antimicrobial and antifouling efficacy of urinary
769 catheters impregnated with a combination of macrolide and fluoroquinolone antibiotics
770 against *Pseudomonas aeruginosa*. *Biofouling* 32: 511-522.
- 771 61. Francesko A, Fernandes MM, Ivanova K, Amorim S, Reis RL, et al. (2016) Bacteria-
772 responsive multilayer coatings comprising polycationic nanospheres for bacteria
773 biofilm prevention on urinary catheters. *Acta biomaterialia* 33: 203-212.

- 774 62. Rajkumar D, Rubini D, Sudharsan M, Suresh D, Nithyanand P (2020) Novel thiazolinyln-
775 picolinamide based palladium (II) complex-impregnated urinary catheters quench the
776 virulence and disintegrate the biofilms of uropathogens. *Biofouling* 36: 351-367.
- 777 63. Karchmer TB, Giannetta ET, Muto CA, Strain BA, Farr BM (2000) A randomized
778 crossover study of silver-coated urinary catheters in hospitalized patients. *Archives of*
779 *Internal Medicine* 160: 3294-3298.
- 780 64. Yassin MA, Elkhoody TA, Elsherbiny SM, Reicha FM, Shokeir AA (2019) Facile coating
781 of urinary catheter with bio-inspired antibacterial coating. *Heliyon* 5: e02986.
- 782 65. Nicolle LE (2012) Urinary catheter-associated infections. *Infectious disease clinics of*
783 *North America* 26: 13-27.
- 784 66. Gurunathan S, Han JW, Kwon D-N, Kim J-H (2014) Enhanced antibacterial and anti-
785 biofilm activities of silver nanoparticles against Gram-negative and Gram-positive
786 bacteria. *Nanoscale research letters* 9: 1-17.
- 787 67. Dakal TC, Kumar A, Majumdar RS, Yadav V (2016) Mechanistic basis of antimicrobial
788 actions of silver nanoparticles. *Frontiers in microbiology* 7: 1831.
- 789 68. Maharjan G, Khadka P, Siddhi Shilpakar G, Chapagain G, Dhungana GR (2018) Catheter-
790 associated urinary tract infection and obstinate biofilm producers. *Canadian Journal of*
791 *Infectious Diseases and Medical Microbiology* 2018.
- 792 69. Manikandan M, Wu H-F (2013) Rapid differentiation and quantification of live/dead cancer
793 cells using differential photochemical behavior of acridine orange. *Photochemical &*
794 *Photobiological Sciences* 12: 1921-1926.
- 795 70. Slavin YN, Asnis J, Häfeli UO, Bach H (2017) Metal nanoparticles: understanding the
796 mechanisms behind antibacterial activity. *Journal of nanobiotechnology* 15: 1-20.

- 797 71. Tamayo L, Zapata P, Vejar N, Azócar M, Gulppi M, et al. (2014) Release of silver and
798 copper nanoparticles from polyethylene nanocomposites and their penetration into
799 *Listeria monocytogenes*. *Materials Science and Engineering: C* 40: 24-31.
- 800 72. Rothstein A (1971) Sulfhydryl groups in membrane structure and function. *Current topics*
801 *in membranes and transport*: Elsevier. pp. 135-176.
- 802 73. Lee SH, Jun B-H (2019) Silver nanoparticles: synthesis and application for nanomedicine.
803 *International journal of molecular sciences* 20: 865.
- 804 74. Sriram MI, Kalishwaralal K, Barathmanikanth S, Gurunathani S (2012) Size-based
805 cytotoxicity of silver nanoparticles in bovine retinal endothelial cells. *Nanoscience*
806 *Methods* 1: 56-77.
- 807 75. Abuayyash A, Ziegler N, Gessmann J, Sengstock C, Schildhauer TA, et al. (2018)
808 Antibacterial Efficacy of Sacrificial Anode Thin Films Combining Silver with Platinum
809 Group Elements within a Bacteria- Containing Human Plasma Clot. *Advanced*
810 *Engineering Materials* 20: 1700493.
- 811 76. Kim S-H, Lee H-S, Ryu D-S, Choi S-J, Lee D-S (2011) Antibacterial activity of silver-
812 nanoparticles against *Staphylococcus aureus* and *Escherichia coli*. *Microbiology and*
813 *Biotechnology Letters* 39: 77-85.
- 814 77. Chen D, Qiao X, Qiu X, Chen J (2009) Synthesis and electrical properties of uniform silver
815 nanoparticles for electronic applications. *Journal of materials science* 44: 1076-1081.
- 816 78. Khatoon Z, McTiernan CD, Suuronen EJ, Mah T-F, Alarcon EI (2018) Bacterial biofilm
817 formation on implantable devices and approaches to its treatment and prevention.
818 *Heliyon* 4: e01067.
- 819 79. Yun'an Qing LC, Li R, Liu G, Zhang Y, Tang X, et al. (2018) Potential antibacterial
820 mechanism of silver nanoparticles and the optimization of orthopedic implants by
821 advanced modification technologies. *International journal of nanomedicine* 13: 3311.

- 822 80. Farah MA, Ali MA, Chen S-M, Li Y, Al-Hemaid FM, et al. (2016) Silver nanoparticles
823 synthesized from *Adenium obesum* leaf extract induced DNA damage, apoptosis and
824 autophagy via generation of reactive oxygen species. *Colloids and Surfaces B:*
825 *Biointerfaces* 141: 158-169.
- 826 81. Gordon O, Vig Slenters Tn, Brunetto PS, Villaruz AE, Sturdevant DE, et al. (2010) Silver
827 coordination polymers for prevention of implant infection: thiol interaction, impact on
828 respiratory chain enzymes, and hydroxyl radical induction. *Antimicrobial agents and*
829 *chemotherapy* 54: 4208-4218.
- 830 82. Raja A, Ashokkumar S, Marthandam RP, Jayachandiran J, Khatiwada CP, et al. (2018)
831 Eco-friendly preparation of zinc oxide nanoparticles using *Tabernaemontana divaricata*
832 and its photocatalytic and antimicrobial activity. *Journal of Photochemistry and*
833 *Photobiology B: Biology* 181: 53-58.
- 834 83. Karygianni L, Ren Z, Koo H, Thurnheer T (2020) Biofilm matrixome: extracellular
835 components in structured microbial communities. *Trends in Microbiology* 28: 668-681.
- 836 84. Kassinger SJ, Van Hoek ML (2020) Biofilm architecture: An emerging synthetic biology
837 target. *Synthetic and systems biotechnology* 5: 1-10.
- 838 85. Carnerero JM, Jimenez- Ruiz A, Castillo PM, Prado- Gotor R (2017) Covalent and Non-
839 Covalent DNA–Gold- Nanoparticle Interactions: New Avenues of Research.
840 *ChemPhysChem* 18: 17-33.
- 841 86. Koo KM, Sina AA, Carrascosa LG, Shiddiky MJ, Trau M (2015) DNA–bare gold affinity
842 interactions: mechanism and applications in biosensing. *Analytical Methods* 7: 7042-
843 7054.
- 844 87. Jiang W-Y, Ran S-Y (2018) Two-stage DNA compaction induced by silver ions suggests
845 a cooperative binding mechanism. *The Journal of chemical physics* 148: 205102.

- 846 88. Tian H, Liao Q, Liu M, Hou J, Zhang Y, et al. (2015) Antibacterial activity of silver
847 nanoparticles target sara through srna-teg49, a key mediator of hfq, in staphylococcus
848 aureus. *International journal of clinical and experimental medicine* 8: 5794.
- 849 89. Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, et al. (2012) The molecular mechanism of action
850 of bactericidal gold nanoparticles on *Escherichia coli*. *Biomaterials* 33: 2327-2333.
- 851 90. Mohanta YK, Biswas K, Jena SK, Hashem A, Abd_Allah EF, et al. (2020) Anti-biofilm
852 and antibacterial activities of silver nanoparticles synthesized by the reducing activity
853 of phytoconstituents present in the Indian medicinal plants. *Frontiers in Microbiology*
854 11.
- 855 91. Rodríguez-Serrano C, Guzmán-Moreno J, Ángeles-Chávez C, Rodríguez-González V,
856 Ortega-Sigala JJ, et al. (2020) Biosynthesis of silver nanoparticles by *Fusarium scirpi*
857 and its potential as antimicrobial agent against uropathogenic *Escherichia coli* biofilms.
858 *Plos one* 15: e0230275.
- 859 92. Joshi AS, Singh P, Mijakovic I (2020) Interactions of gold and silver nanoparticles with
860 bacterial biofilms: Molecular interactions behind inhibition and resistance.
861 *International Journal of Molecular Sciences* 21: 7658.
- 862 93. Kalishwaralal K, BarathManiKanth S, Pandian SRK, Deepak V, Gurunathan S (2010)
863 Silver nanoparticles impede the biofilm formation by *Pseudomonas aeruginosa* and
864 *Staphylococcus epidermidis*. *Colloids and Surfaces B: Biointerfaces* 79: 340-344.
- 865 94. Singh R, Hano C, Nath G, Sharma B (2021) Green Biosynthesis of Silver Nanoparticles
866 Using Leaf Extract of *Carissa carandas* L. and Their Antioxidant and Antimicrobial
867 Activity against Human Pathogenic Bacteria. *Biomolecules* 11: 299.
- 868 95. John A, Shaji A, Vealyudhannair K, Nidhin M, Krishnamoorthy G (2021) Anti-bacterial
869 and biocompatibility properties of green synthesized silver nanoparticles using *Parkia*

870 biglandulosa (Fabales: Fabaceae) leaf extract. Current Research in Green and
871 Sustainable Chemistry: 100112.

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895 **Table 1** Antibacterial activity against Uropathogens

896	Bacteria	ZoI of <i>C. carandas</i> (mm)				
		25µg/ml	50µg/ml	75 µg/ml	100µg/ml	125 µg/ml
898	<i>S. aureus</i>	8±0.3	10 ±0.3	13 ±0.3	15 ±0.3	17 ±0.1
899	<i>E. coli</i>	10 ±0.1	13 ±0.2	13 ±0.2	13 ±0.3	15 ±0.2
900	<i>P. aeruginosa</i>	8 ±0.2	9 ±0.2	10 ±0.5	13 ±0.2	15 ±0.1

905 **Table 2** Comparative analysis against Uropathogens (ZOI)

Strains	ZoI of <i>C. carandas</i> (mm)					
	Crude extract	AgNo3	AgNPs	Ciprofloxacin	Uncoated catheter	AgNPs Coated Catheter
<i>S. aureus</i>	-	11 ±0.3	17±0.2	16±0.3	No zone	17±0.4
<i>E. coli</i>	-	13±0.1	21±0.3	17±0.2	No zone	21±0.3
<i>P. aeruginosa</i>	-	10±0.4	13±0.3	10±0.1	No zone	13±0.1

906

907

908

909

910

911

912

913

914

915 **Table 3** Zone of Inhibition of different antibiotics against uropathogens with presence and
 916 absence of AgNPs.

917

Strains	Antibiotics	ZoI (mm)		
		Antibiotics (a)	Antibiotic + AgNPs (b)	Increase in fold area ($b^2 - a^2/a^2$)
<i>S. aureus</i>	Ciprofloxacin	16	19	0.41
	Gentamycin	27	29	0.15
	Trimethoprim	No zone	11	2.3
<i>E. coli</i>	Ciprofloxacin	22	24	0.19
	Gentamycin	19	20	0.10
	Trimethoprim	7	10	1.04
<i>P. aeruginosa</i>	Ciprofloxacin	23	25	0.18
	Gentamycin	16	19	0.41
	Trimethoprim	5	11	3.84

918

919

920

921

922

923

924

925

926

927

928 **Figure legends**

929 **Fig 1.** UV-visible spectra of *Carissa carandas* leaf mediated synthesized AgNPs (before
930 optimization procedure), AgNO₃, *Carissa carandas* leaf extract.

931 **Fig 2.** UV – vis spectra of aqueous AgNO₃ with *Carissa carandas* leaf extract at (A)different
932 pH (B) different substrate concentration (C) different silver ion concentration (D) different time
933 intervals.

934 **Fig 3.** Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using
935 (A)EDX (B) XRD.

936 **Fig 4.** Characterization of AgNPs synthesized using *Carissa carandas* leaf extract using
937 (A)TEM (B) Histogram (C) SAED (D) FTIR

938 **Fig 5.** Antibacterial activity of different concentrations of *C. carandas* mediated synthesized
939 AgNPs against the test pathogens. (1) Zone of Inhibition in different concentrations
940 (A-25µg/mL, B-50 µg/mL, C-75 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against
941 *Escherichia coli* AMB4. (2) Zone of Inhibition in different concentrations (A-25µg/mL, B-50
942 µg/mL, C-75 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against *Staphylococcus aureus*
943 AMB6. (3) Zone of Inhibition in different concentrations (A-25µg/mL, B-50 µg/mL, C-75
944 µg/mL, D-100 µg/mL, E-125 µg/mL) of AgNPs against *Pseudomonas aeruginosa* AMB5

945 **Fig 6.** Antibacterial comparison of *C. carandas* mediated synthesized AgNPs, commercial
946 antibiotics (ciprofloxacin), *C. carandas* leaf extract, AgNO₃ against test pathogens.
947 (1) Zone of inhibition observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and
948 commercial antibiotic (ciprofloxacin) against *Escherichia coli* AMB4. (2) Zone of inhibition
949 observed in the well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic
950 (ciprofloxacin) against *Staphylococcus aureus* AMB6. (3) Zone of inhibition observed in the

951 well of AgNPs, solvent control (DMSO), AgNO₃ and commercial antibiotic (ciprofloxacin)
952 against *Pseudomonas aeruginosa* AMB5.

953 **Fig 7.** Minimum inhibitory concentration for different concentrations (20, 40, 60, 80, 100, 120,
954 140, and 160µg/ml) of AgNPs against *Escherichia coli* AMB4, *Pseudomonas aeruginosa*
955 AMB5, *Staphylococcus aureus* AMB6.

956 **Fig 8.** Urinary catheter coated with AgNPs and uncoated catheter (A) *C. carandas* leaf
957 mediated synthesized AgNPs coated urinary catheter of size 1× 1 cm (B) uncoated urinary
958 catheter of size 1×1 cm

959 **Fig 9.** Biofilm inhibition percentage of AgNPs coated catheter. AgNPs coated catheter with
960 different concentration of 20,40,80,120,160 µg/mL shows biofilm inhibition towards
961 *Escherichia coli* AMB4, *Pseudomonas aeruginosa* AMB5, *Staphylococcus aureus* AMB6.

962 **Fig 10.** SEM analysis of urinary catheter (A) SEM micrograph of uncoated urinary catheter
963 (control) (B) SEM micrograph of urinary catheter coated with 30 µg/mL of AgNPs, arrow
964 indicate the coating of AgNPs (C) SEM micrograph of biofilm mat formed by *Escherichia coli*
965 AMB4 over uncoated urinary catheter, arrow indicates the mat formation (D) SEM micrograph
966 showing the disruption of biofilm formed by *Escherichia coli* AMB4 over AgNPs coated
967 urinary catheter, arrow indicates the disruption of biofilm.

968 **Fig 11.** Proposed antibacterial mechanism of plant mediated AgNPs showing various
969 inhibiting properties of AgNPs. 1) AgNPs interact with ribosome and inhibit the translation; 2)
970 AgNPs have electrostatic interaction with the cell wall which ultimately causes the leakage of
971 internal substances; 3) AgNPs interact with sulfhydryl group of enzymes and proteins, hence
972 protein denaturation takes place; 4) AgNPs inactivates the respiratory chain and excess ROS
973 generation, results in the apoptosis; 5) AgNPs anchor the cell wall of the bacteria and causes
974 damages to the cell membrane and the cellular content get leaked.

975 **Fig 12.** Proposed antibiofilm mechanism of plant mediated AgNPs. (1) AgNPs has
976 electrostatic interaction with the cells and disturb the biofilm formation; (2) AgNPs penetrate
977 the biofilm and creates anti-adherence which ultimately cause the leakage of cellular contents;
978 (3) AgNPs degrade the EPS formation and breaks the biofilm mat; (4) AgNPs inhibits the signal
979 produced by the bacteria, thereby inhibiting the biofilm formation.

980

981

Plos One Journal Modifications

1. Revised manuscript has been changed to the style requirements of PLOS ONE
2. Tables has been included in the revised manuscript and removed separate file
3. We didn't receive any funding for this work so please change it to "The authors received no specific funding for this work"
4. Minimal data set has been included as a supplementary file.
5. The figure 10,11 is similar but not identical to the original image and is therefore for illustrative purpose only and the figure 5 has been changed in the revised manuscript.

Response to reviewers comments

We are thankful to the Reviewers 1,2, and 3 for their kind and constructive feedback. As suggested by the reviewers, we have changed/addressed the following comments and the same has been highlighted in the revised manuscript with the response to the reviewers' file.

No	Page/Section	Comments by Reviewer #1	Response by the authors
1	Introduction	In the introduction, authors should justify why they decided to use Ag NPs and leaves of <i>C. carandas</i> ? Highlight their advantages, because we cannot simply use something because just it is available!	We have improved the introduction part as per your suggestion. Reviewer can find the improved part at line 76-79 and line 86-94 in the revised manuscript.
2	Line 60	Line 60, "Leaves of <i>C. carandas</i> were used to yield Ag NPs", I think you need to rephrase this sentence, as leaf extract can only be used to stabilize formed Ag NPs and / or reduce the precursor solution of silver nitrate into Ag NPs.	We have rephrased the sentence and can be found at line 95-97 of the revised manuscript.
3	Line 93	Line 93, wavelength of Cu-K α radiation is not correct, the correct value is 1.5406 Å	Correct value can be found at line 141 in the revised manuscript
4	Line 225-line 93	In line 225, authors used Scherrer formula to determine crystalline size, and they mentioned non-correct wavelength in Line 93, then accordingly, the calculated size will not be correct. Please check this size again.	The wavelength has been corrected in line 141 of revised manuscript. Therefore, size mentioned in the line 313 of revised manuscript doesn't need any modification
5		XRD pattern contains non-assigned peaks, please explain.	Detailed description was made and can be found at line 316-320 in the revised manuscript
6		on FTIR spectra, it is better to highlight, peaks confirming the conjugation between Ag NPs and the extract	Highlighted peaks confirm the capping can be found at Fig 4 D in the revised manuscript
7		On SAED pattern, you should assign the crystalline planes and match them with those obtained by XRD.	Fig 4 C of the revised manuscript shows the marked diffraction rings corresponds to the peaks obtained in XRD

8	Fig.2	Fig. 2 is not clear; it is better to draw the data using suitable software	Suggested modifications were done in the revised manuscript and can be found as Fig 2 and Fig 3
9	Fig. 3	Fig. 3 it is hard to see the label, also indicate the ZOI on the figure for each tested sample.	Suggested modification are done in the revised manuscript and can be found as Fig 4 and Fig 5
10	Fig.4	Fig.4, error bars should be added	Suggested modification are done in the revised manuscript and can be found as Fig 7
11	Fig. 9	On Fig. 9, assign Ag NPs.	Suggested modifications are done in the revised manuscript and can be found as Fig 10

No	Page/Section	Comments by Reviewer #2	Response by the authors
1	Fig 10	The Fig 10 is inappropriate, require evidence-based pathway	The actual mechanism was not found through our study but we are coming up with the mechanism already available in the literature and we have changed the text in figure instead of <i>Carisa carandas</i> AgNPs it is mentioned as plant AgNPs and also, we have widely discussed about the biofilm mechanism in the discussion part line 545-564
2		Light Microscopy and Florescent Microscopy images shall be placed under suppl doc	It is placed under supplementary file as per your suggestion and can be found as Supplementary document in the revised manuscript
3		Include CFLSM image for biofilm inhibition	As stated in the financial disclosure this study does not have any funding it is very hard for us to afford this imaging as it is not available in our institutions. However, we will try to sort out this issue in the future studies.
4		TEM is showing a cluster of AgNPs, required scale marked particles	Suggested modifications by the reviewer has been done and can be found at Fig 4 (A) in the revised manuscript
5		Self-agglomeration of synthesized AgNPs on storage is required	We have found the AgNPs solution was stable for the period of two months under dark. Hence no agglomeration

			was taken place in the solution and then we lyophilized the AgNPs to obtain AgNPs powder for the purpose of application. Therefore, no chance of self-agglomeration takes place
6		Language and presentation require editing e.g. In the Introduction Pseudomonas is written as Pseudomonas as	All the necessary modifications were done in the revised manuscript

No	Page/Section	Comments by Reviewer #3	Response by the authors
1		All minor revisions are highlighted in manuscript file, these include suggestion for rewrite sentences, and simple changes	All the minor revisions were changed according to the suggestion of the reviewer in the revised manuscript
2		Abstract and introduction Grammar revision is suggested in some parts of these sections, in manuscript file are highlighted in yellow.	The grammar revisions were changed according to the suggestion of the reviewer in the revised manuscript
3		Synthesis and optimization of AgNPs production Include units of Ag ion concentration, volume of leaf extract, etc.	Suggested modifications by the reviewer has been done in the revised manuscript and can be found at line 122-134
4		Antibacterial activity I suggest modification of titles and subtitles order, and include some methodology description described in other method section. Include description about how the AgNPs concentration was calculated.	Suggested modifications by the reviewer has been done and can be found at line 154-162 in the revised manuscript
5		Biofilm inhibition assay Indicate concentration of AgNPs in concentration units (i.e. mg/L) instead of volume units. If concentration and volume of AgNPs are equivalent please indicate and explain	Suggested modifications by the reviewers has been done and can be found at line 224-226 and at line 237-250 in the revised manuscript
6		In Section 2.12 it is not clear the objective of this experiment, please justify.	The experiment title has been changed and the objective has been well described at line 252-256 in the revised manuscript
7		Results I suggest to maintain the same subtitles used in methods section in order to establish an order and accordance between methods and results	As per the reviewer's suggestion, we have maintained the same subtitles in methods and results which can be found in the revised manuscript

8		I suggest include images of AgNPs suspensions obtained at different synthesis conditions (i.e. varying pH, leaf extract concentration, time reaction and Ag ions concentration)	As per the reviewer suggestion the image for color of AgNPs synthesis has been added in Fig 1 and Fig 2 (A, B, C, D)
9		I consider it is necessary to provide clear description of parameters used in each optimization condition of results obtained and presented in fig 1	Suggested modifications by the reviewer has been done and can be found at line 273-300 in the revised manuscript
10		I considered necessary to clearly indicate which are the optimal parameters selected for AgNPs synthesis and criteria used for the establishment of these parameters.	Suggested modifications by the reviewer has been done and can be found at line 273-300 in the revised manuscript
11		It is not clear how the average size of AgNPs observed by HR-TEM was calculate, please include description.	Suggested modifications by the reviewer has been done and can be found at line 341-346 in the revised manuscript
12		I suggest to include information about how the MICs were calculated?	Suggested comments by reviewers has been addressed and can be found at line 174-184 in the revised manuscript
13		The fig 4 shows an important inhibition of bacterial growth (O.D.) at 160 mg/L however higher concentration must be proved in order to establish the MICs. I suggest include O.D. measurements of cultures exposed to higher concentrations of AgNPs to obtain a 100% of growth inhibition and establish the MICs	Suggested comments by the editor has been addressed and can be found at line 355-374 in the revised manuscript
14		Description of results obtained by SEM must be wide described based on the results presents in figure 9.	Suggested comments by the editor has been addressed and can be found at line 414-421 in the revised manuscript
15		I suggest that the section of results 3.10 (Mechanisms of antibacterial and antibiofilm activity of AgNPs) must be eliminated and included and well describer in discussion section.	Suggested modifications by the reviewers has been well addressed and can be found at line 514-564 in the revised manuscript
16		Discussion I suggest general revision of grammar of these sections, some parts of the text are not understandable. (yellow highlighted)	Suggested modifications by the reviewers has been addressed in the revised manuscript
17		Lines 328-329 Question: With SPR intensity do you refer to intensity in colour? or intensity of the peak absorption in spectra? if you refer to the color, you must provide the	Color image of AgNPs suspension has been included in the Fig 2 (A, B, C, D)

		images of AgNPs suspensions. if you refer to the absorption peak, in figure 1a a variation of peak intensity and wavelength of maximum absorption was clearly observed, thus an effect of pH in the intensity of absorption peak is produced.	
18		Lines 327-340 I consider that based on FTIR results, probable phyto molecules involved in stabilization and capping of AgNPs must be provided and make a comparison with results obtained in previous studies on which phytosynthesis of AgNPs was carried out.	Suggested modifications by the reviewers has been addressed at line 454-464 in the revised manuscript
19		Lines 346-347 I consider is important to indicate how the particle size average was determined, HR-TEM indicate certain grade of heterogeneity of particle size, and in this part of discussion you describe that AgNPs are homogeneous in size, however in conclusion section a size heterogeneity of AgNPs was mentioned. Please describe results, discussion and conclusion according to the data obtained.	Suggested modifications by the reviewers has been addressed at line 473-476 and 341-347 in the revised manuscript
20		Line 358 I consider that a wide discussion based on the scientific literature about the efficiency of AgNPs coated catheters against UTIs must be provided.	Suggested modifications by the reviewers has been addressed at line 487-494 in the revised manuscript
21		Line 378 I consider that a wide description of the figure 10 was necessary, adapt the information provided below to the mechanisms described in figure.	Suggested modifications by the reviewers has been addressed at line 545-564 in the revised manuscript
22		Line 386-394 I consider that this part of discussion must include comparison of the previous studies described with the results obtained in this work. And include a wide discussion about phyto molecules involved in AgNPs synthesis.	Suggested modifications by the reviewers has been addressed at line 565-570 in the revised manuscript
23		Conclusions I suggest rewrite the conclusions, cause I consider that some conclusions show discrepancy with the results and	Conclusion has been rewritten and can be found at line 575-585 in the revised manuscript

		discussion, some of this conclusions are not supported by data presented.	
24		<p>Figures and tables</p> <p>In general I suggest to improve the figure description, in order to be clear, informative and to support the description of the results. Also improve of resolution is recommended.</p>	<p>As per the suggestions of reviewer all the images were replaced with better resolution and detailed figure description has been provided in the revised manuscript</p>

The revised manuscript as per the reviewer comments has been resubmitted to your journal. We look forward to your positive response.

Sincerely,

Dr. Muthupandian Saravanan